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I N T R O D U C T I O N  
NATURAL COMPOUNDS AND PHARMACOLOGY 
Around 80% of the world population, mainly in the non-developed countries, has the 
first option for medication in Primary Health Care in natural products (Mahady, 2001). 
Natural products, as disease remedies, have a history of nearby 5000 years (India, China 
and Greece), whereas isolated pure chemicals or synthetic drugs have been around for 
100 years, since Bayer synthesized acetylsalicylic acid (aspirin) at the end of XIX 
century. Nowadays, around half of the drugs currently in clinical use are of natural 
product origin (Butler, 2005; Newman et al., 2003) and nutraceuticals, i.e. ‘natural’ 
substances isolated or purified from food and used in a medicinal fashion, have 
appeared on the market. These nutraceuticals are pharmaceutical preparations (pills, 
powders, capsules, vials, etc) containing food bioactive compounds as active principles. 
Scientific research has supported the biological activity of many of these food 
phytochemicals; in fact several naturally derived food substances have been studied, 
showing an extensive spectrum of biological activities such as stimulation of the immune 
system, anti-bacterial, anti-viral, anti-hepatotoxic, anti-ulcer, anti-inflammatory, anti-
oxidant, anti-mutagenic, and above all anti-cancer effects (Miyata, 2007; Espín et al., 
2007). Cancer is mostly a preventable disease (Glade, 1999). One of the most important 
ways to reduce cancer risk is the habitual consumption of foods containing bioactive 
compounds that protect against cancer. Several studies have documented the 
relationship between decreased cancer risk and high consumption of vegetables, 
including cabbage, cauliflower, broccoli, brussels sprout, tomatoes, and fruits such as, 
apples, grapes, and berries (Vainio and Weiderpass, 2006; Gordaliza, 2007). 
Furthermore, a variety of grains, cereals, nuts, soy products, olives, beverages such as 
tea and coffee, and spices including turmeric, garlic, ginger, black pepper, cumin and 
caraway confer a protective effect against cancer (Lila, 2007; Williams and Hord, 2005). 
Vitamin E, selenium, vitamin D, green tea, soy, and lycopene have all been examined in 
human studies and in general, it is possible to say that natural products consist of a wide 
variety of biologically active phytochemicals including phenolics, flavonoids, 
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carotenoids, alkaloids and nitrogen containing as well as organosulfur compounds, 
which have been shown to alter carcinogenesis (Table 1) (Nishino et al., 2007). 
Table 1. Source, mechanism of action, molecular targets, and cancer type target of some of the 
more promising antitumoral natural compounds (adapted from Amin et al., 2009). 
 
In this framework, cancer chemotherapy presents an ideal opportunity for natural 
product–inspired drug discovery and development. An ideal cancer chemopreventive 
agent should have little or no toxicity, high efficacy in multiple sites, capability of oral 
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consumption, known mechanisms of action, low cost, and human acceptance. Indeed, in 
recent years, natural products have received great attention for cancer prevention 
owing to their various health benefits, noticeable lack of toxicity and side effects, and the 
limitations of chemotherapeutic agents (Manson et al., 2005). 
Unfortunately, many of the most promising natural compounds are available only in 
extremely small quantities, especially those from marine organisms such as sponges. In 
the last few years, intense research efforts have been devoted to overcome the limits 
imposed by nature. There are two main targets of this research: large-scale production 
and the optimization of the intrinsic biological activity of a natural product. A successful 
example of improvement in production strategy is the microtubule-stabilizing agent 
discodermolide that is available only in minute amounts from its natural origin (a 
marine sponge). Through the continued evolution and optimization of synthesis 
strategies, discodermolide is now available in the desired amount (Paterson and 
Florence, 2003; Smith III et al., 2000). Optimization of the intrinsic biological activity of a 
natural product implies the design and the preparation of natural product analogs that 
allow us to tailor and enhance the drug-like properties (bioactivity, pharmacokinetics, 
solubility, etc.) of the natural active principles. Not only structural modifications can 
lead to biologically effective drug candidates, but also permutations, including structural 
simplification with the removal of unneeded functional groups and stereochemistry, 
facilitating chemical synthesis. A fine example of a natural product-inspired drug 
candidate is the potent oncolytic (cancer cell-killing) agent E7389, currently in phase I 
clinical trials. E7389 arose from extensive studies aimed to remove unneeded functional 
groups from halichondrin B (Aicher et al., 1992), a highly cytotoxic and complex marine 
natural product in order to simplify chemical synthesis. Another example is the design 
and development of a new class of anticancer drugs that mimic the Smac motif and act as 
antagonist of inhibitor of apoptosis proteins (Li et al., 2004; Sun et al., 2004).  
Of course, the opportunities for the preparation of natural product analogs are not 
restricted to the discovery of anti-cancer drug candidates. For example, in the case of 
anti-infectives, analog design may allow us to circumvent drug resistance, in a manner 
that again cannot be matched by standard methods for antibiotic development (Charest 
et al., 2005).  
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Why do natural products possess such extraordinary specificity and potency compared 
to artificially designed molecules? The answer lies in evolutionary selection, nature's 
own high-throughput screening process for the optimization of biologically active 
compounds. Natural products tend to possess well-defined three-dimensional 
structures, embellished with functional groups (providing hydrogen bond 
acceptor/donors, etc.), which have been fine-tuned into a precise spatial orientation. 
Additionally, the structures of the biological targets of such natural products (e.g., 
protein binding sites) are often well conserved among proteins of markedly different 
genetic sequences (Zhang and DeLisi, 1998; Anantharaman et al., 2003), so much so that 
metabolites that have evolved for a certain purpose and mode of action by a producing 
organism may exert different, yet equally potent, effects in other settings.  
In conclusion, the continued isolation of an increasing range of novel bioactive 
metabolites suggests that the plant kingdom represents an immense reservoir of 
potentially powerful therapeutic agents whose surface has been barely scratched. 
TOMATO AS PHYTOTHERAPIC 
Tomato was introduced in human diet approximately five hundred years ago and during 
the last two centuries has become one of the most important horticultural crops due to 
the worldwide consumption of its fruit and products such as sauces, tomato paste, 
canned tomatoes and juices. Many tomato products are good sources of potassium, 
folate, and the vitamins A, C, and E, as demonstrated in Table 2 (USDA Nutrient Data 
Bank).  
Table 2. Nutrient composition of tomatoes and related tomato products (from USDA Nutrient 
Data Bank)  
 
2 USDA Nutrient Data Bank numbers: raw tomatoes 11529; catsup 11935; tomato juice 11540; tomato 
sauce 11549; tomato soup 6359 
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In comparison with the other regularly consumed vegetables, only carrots are a better 
dietary source of vitamin A than tomato-based foods. In addition to their micronutrient 
benefits (vitamins, minerals, etc.), tomatoes also contain valuable phytochemicals, 
including carotenoids and polyphenols. For instance, carotenoids, such as the red 
pigmented lycopene, -carotene, a pro-vitamin A, phytoene, and phytofluene are all 
found in abundance in raw tomatoes and tomato products (USDA Nutrient Data Bank; 
Tonucci et al., 1995). Several studies have indicated that regular consumption of tomato 
fruit is consistently associated with lower risk of cardiovascular disease and several 
types of cancer, including prostate cancer (Etminan et al., 2004; Hwang and Bowen, 
2002). Rather, with prostate cancer, tomato appears the appropriate food choice that 
can slow the onset of the disease and that can play a role in prevention (Wilkinson and 
Chodak, 2003; Cohen, 2002). Although tomato phytochemicals are thought to contribute 
to the reduced risk of human diseases, the active principles of tomato fruit have eagerly 
been searched, but their identification is still incomplete. -carotene and lycopene have 
been indicated as putative active principles, however evidence of their role as the main 
cardio-protective and/or anti-cancer principle is either negative or not conclusive 
(Canene-Adams et al., 2007). In fact, evidence suggests that lycopene by itself might 
have some anti-prostate cancer activity or might be protective against lipid 
peroxidation, but tomato fruit effects are superior to those of pure carotenoid(s) 
(Canene-Adams et al., 2007; Alshatwi et al., 2010). In the light of this evidence, it is 
possible that other bioactive compounds present in tomato fruit contribute to the anti-
cancer and anti-inflammatory properties of tomato fruit. Peptides and proteins present 
in tomato fruit have received little attention even though such compounds might have 
biological activity in human cells. 
 
CYSTINE-KNOT MINIPROTEINS 
Cystine-knot miniproteins are members of a large family of small proteins widespread in 
plant and animal species; they display a multitude of therapeutically useful biological 
activity. Cystine-knot miniproteins typically consist of less than 50 amino acids and they 
have a unique three-dimensional structure characterized by three intra-molecular 
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disulfide bonds forming a cystine-knot and a small tripled stranded -sheet (Craik, 
2001). The cystine-knot acts as structural scaffold for the whole protein or for one of its 
domains conferring to the cystine-knot miniproteins a compact and remarkably stable 
structure in the face of extreme pH, chemical and thermal denaturation, and proteolytic 
attack (Ireland et al., 2006; Werle et al., 2007). Naturally occurring cystine-knot 
miniproteins, despite their similar molecular structure, feature a multitude of different 
biological functions. In animals, cystine-knot miniproteins include factors that function 
as extracellular ligand and regulate numerous cellular functions such as cell growth and 
development (Vitt et al., 2001). In plants, cystine-knot miniproteins are often involved in 
resistance to pathogens with the function of protease inhibitors or as elicitors of defence 
responses against pathogens (Norton and Pallaghy, 1998; Quilis et al., 2007).  
There are two classes of cystine-knots: growth factors cystine knot and inhibitor 
cystine-knots, which includes the cyclotide (cyclic cystine knot; Figure 1). The 
penetrating disulfide bond for the cystine-knot growth factors is Cys I-IV whereas it is 
Cys III-VI in the cystine-knot inhibitors and cyclic cystine-knot miniproteins. 
The cysteine interlocked connectivity is necessary but not sufficient to ensure the 
membership of the family; indeed for example, each of the 4 domains of wheat germ 
agglutinin have such a connectivity but with a planar spiral topology (Wright, 1981) and 
so it is not a cystine-knot miniprotein. 
 
Figure 1. Schematic diagrams of the three groups of cystine-knot miniproteins. The -strands 
are drawn as arrows, the cysteine residues are labeled I-VI from the N- to C-terminus and the 
disulfide bonds are colored in yellow.  (from web site www.cyclotide.com/knots.html). 
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Cystine-knot miniproteins display a broad spectrum of therapeutically useful natural 
biological activities and several members of this family are marketed as therapeutics or 
are in clinical development (Gustafson et al., 2004; Krause et al., 2007). To extend the 
broad range of natural biological activities of cystine knot miniproteins to those with 
therapeutic relevance, several pieces of protein engineering research have been 
reported. The cystine-knot framework, owing to its inherent thermal and biological 
stability, is an attractive scaffold for the design of stable, functional small proteins for 
pharmaceutical applications. One of the major advantages of this scaffold lies in the fact 
that the cystine-knot core is a reproducible structural unit that can be functionalized by 
decoration with bioactive loop residues. Miniprotein loops tolerate the substitution of 
individual amino acids as well as the insertion of additional amino acids (Cwirla et al., 
1997; Krause et al., 2007; Christmann et al., 1999). Because the knottin scaffold retains 
its rigid structure upon loop modification, structure-based modelling and optimisation 
of miniprotein binding to the target protein is feasible.  
Alternatively, the natural bioactivity of a given cystine-knot miniprotein can be used as a 
starting point for improvement of the pharmacologic properties. The main advantage of 
using cystine-knot miniprotein for pharmaceutical applications lies in the fact that high 
affinities (up to the picomolar range) and selectivities can be obtained. Moreover, many, 
but not all, cystine-knot miniproteins are stable against proteolytic attack and display 
high plasma stabilities in comparison with other proteins and peptides. They can be 
boiled, incubated at 65°C for weeks, or even placed in 1N HCl or 1N NaOH, without loss 
of structural and functional integrity (Werle et al., 2007; Heitz et al., 2008; Kimura et al., 
2009; Wang et al., 2009). Many cystine-knot miniproteins are per se resistant against 
serum proteases or even against intestinal proteases and therefore could be delivered 
by mouth (Werle et al., 2007; Werle et al., 2008; Werle et al., 2006). 
GROWTH FACTORS CYSTINE-KNOT 
The family of growth factors cystine-knot consists of four distinct sub-families, nerve 
growth factor (NGF; McDonald et al., 1991), transforming growth factor-beta (TGF-; 
Schlunegger and Grütter, 1992; Daopin et al., 1992), platelet-derived growth factor 
(PDGF; Oefner et al., 1992) and the glycoprotein hormones (GPHs). These homo- and 
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hetero-dimeric proteins have a diverse range of effects on cell survival, proliferation and 
differentiation which are mediated via interactions with quite distinct receptor families 
(Figure 2).  
 
Figure 2. Classification of the growth factor cystine-knot superfamily. The abbreviations used 
are: TGF , transforming growth factor-beta;PDGF, platelet-derived growth factor; NGF, nerve 
growth factor; GPH, glycoprotein hormones; S/T, threonine/serine; TK, tyrosine kinase; Ig, 
immunoglobulin-like; Cys, cysteine-rich; TNFR, tumour necrosis factor receptor. ( from Hearn 
and Gomme, 2000) 
 
Comparison of the primary structures of the different members of these four subsets 
indicates that, with the exception of residues associated with the cystine-knot motif, 
there is very little sequence similarity. The N- and C-terminal and loop regions of the 
family members vary both in size and conformation.  
The growth factors have acquired differences in the loops conformation during the 
course of evolution that presumably serve to modulate their biological specificity or that 
enable them to trigger cooperative conformational changes in their cognate receptors as 
part of the process of signal transduction (Pallaghy et al., 1994). 
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INHIBITOR CYSTINE-KNOTS OR KNOTTINS 
The knottins are widespread miniproteins present in many species and featuring 
various biological actions such as protease inhibitory, anti-microbial, insecticidal, 
cytotoxic, anti-HIV or hormone-like activity (Chiche et al., 2004). They share the unique 
knotted topology of three disulfide bridges forming a knot. This scaffold was first 
discovered in 1982 in PCI, a carboxypeptidase inhibitor from potato (Rees and 
Lipscomb, 1982). It has since been observed in a great number of unrelated proteins 
families including, e.g. toxins from plants, bugs, molluscs or arachnids, or anti-microbials 
from plants, insects or arthropods. Proteins sharing this scaffold were referred to as 
knottins (Le Nguyen et al., 1990) or inhibitor cystine-knots (Pallaghy et al., 1994) or 
even simply as cystine-knots. The most populated knottin families are conotoxins (446 
sequences), spider toxins (593 sequences) and cyclotides (165 sequences). A complete 
list of the knottin families is listed in Table 3. 
Table 3. List of the knottin types (from http://knottin.cbs.cnrs.fr/Knottins.php) . 
Type N° of sequences  Type N° of sequences 
Agouti-related 118  Maize 8 
Alpha-amylase 
inhibitor 
1  
Metallo carboxypeptidase 
inhibitor 
13 
Algae 1  Plant antimicrobial 13 
Bacteria 3  Plant defensin 2 
Bug 3  Plant toxin 28 
Conotoxin1 440  Scorpion1 7 
Conotoxin2 5  Scorpion2 47 
Conotoxin3 1  
Serine protease 
inhibitor1 
36 
Cyclotide 165  
Serine protease 
inhibitor2 
4 
Fungi1 12  Spider 593 
Fungi2 20  Sponge 1 
Gumarin-like 1  Trematoda 12 
Horsehoe crab 5  Trichoplax 1 
Insect1 11  Virus1 24 
Insect2 22  Virus2 24 
 
Polypeptides containing the inhibitor cystine-knot motif are of low molecular weight 
and may lack the conformational versatility necessary to participate in cooperative 
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conformational changes upon interaction with their target proteins, behaving therefore 
mainly as inhibitors (Pallaghy et al., 1994). 
The inhibitor cystine-knot motif is composed of an anti-parallel, triple stranded -sheet 
stabilized by a cystine-knot, as shown schematically in Figure 3.  
 
Figure 3. Schematic diagram of the 
inhibitor cystine knot structure. C 
represent a half-cystine residue 
and X represents any other residue. 
(adapted from Pallaghy et al.,  
1994). 
The only highly conserved signature of 
members of the knottin family is the space 
between adjacent cysteine residues and the 
mode of disulfide bond connectivity. The 
backbone loops, however, are variable 
according to length and amino acids sequence. 
A large family of cystine-knot miniproteins 
(cyclotides), exclusively found in plants, has the 
unusual feature of a head-to-tail cyclized 
peptide (Craik et al., 2007; Craik et al., 2006).  
Both open chain and circular miniproteins containing the cystine-knot motif are 
remarkably stable in the face of extreme pH, chemical and thermal denaturation and 
proteolytic attack (Ireland et al., 2006; Werle et al., 2007). This is probably a result of the 
enormous conformational rigidity that is introduced by covalent disulfide linkage of the 
knotted core (Colgrave and Craik, 2004; Krätzner et al.,2005). 
CYCLOTIDES 
The cyclotides (Craik et al., 1999) are a remarkable family of small plant-derived 
proteins that have the unique feature of a circular protein backbone. They typically 
contain 28-37 amino acids linked in continuous circle of peptide bonds and thus contain 
no free N- or C-terminal. The cyclotides are extremely resistant to proteolysis and are 
remarkably stable. These features have led to suggestions that this protein family makes 
an excellent template for drug design application (Craik et al., 2002). Cyclotides with 
haemolytic (Schöpke et al., 1994), cytotoxic (Lindholm et al., 2002), anti-HIV (Gustafson 
et al., 2004) and anti-fouling (Göransson et al., 2004) activities have also been described. 
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They also have exciting potential applications in agriculture because they are potent 
insecticidal agents (Jennings et al., 2001). 
POTATO CARBOXYPEPTIDASE INHIBITORS 
A cystine-knot protease inhibitor was first discovered in 1980 in potato and it was 
shown that this miniprotein acts as a carboxypeptidase inhibitor (Rees and Lipscomb, 
1980). The potato metallo carboxypeptidase inhibitor (PCI) has been by far the best 
characterized at the protein level (Avilés et al., 1993). PCI is a small, 39 amino acid-long, 
globular protein that competitively inhibits several metallo carboxypeptidases with a Ki 
in the nanomolar range (Hass et al., 1979a). The NMR three-dimensional structure of PCI 
in aqueous solution (Clore et al., 1987) and the crystal structure of its complex with 
carboxypeptidase A (Rees and Lipscomb, 1982) has been determined. The 27-residue 
globular core is stabilized by the three disulfide bridges and lacks regular secondary 
structures except for a short 5-residue helix and a very small -sheet. From its 
hydrophobic central core protrudes a C-terminal tail (residues 35-39), which is inserted 
into the active site of the carboxypeptidase and shapes the primary binding site with the 
enzyme. A short stretch of core residues located around Trp28 constitutes the secondary 
binding site (Rees and Lipscomb, 1982). Several studies have demonstrated the 
therapeutic properties of PCI in different diseases. Administration of PCI reduced tissue 
factor-induced renal microthrombosis in rats (Muto et al., 2003); moreover, in vivo anti-
thrombotic efficacy of PCI was demonstrated in murine model: administration of PCI 
inhibits thrombin activatable fibrinolysis inhibitor (TAFI; also known as plasma 
procarboxypeptidase B), the molecule that renders a fibrin-containing thrombus less 
sensitive to lysis (Wang et al., 2006). 
PCI could be a therapeutic agent not only for its inhibitory activity, but also when 
exploited for its knotted structure. In particular, it has been shown that PCI display 
structural homology with mammalian epidermal growth factor (EGF), which makes this 
molecule an EGF antagonist with potential significance as an anti-tumor agent: PCI 
inhibits pancreatic adenocarcinoma cell growth by binding to the epidermal growth 
factor receptor (EGFR) (Blanco-Aparicio et al., 1998; Sitjà-Arnau et al., 2005).  
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Recently it has been demonstrated that potato contains three PCI isoinhibitor families (I, 
II and III) that are closely related. The predominant form (II) is a mixture of two 
polypeptides (IIa and IIb) with the difference in that IIa possessed an additional residue 
of glutamine (Hass et al., 1975). Isoinhibitor I was shown to be identical to II except for 
two replacements (S30A and R32G). These replacements had no significant effect on 
apparent Ki values towards either carboxypeptidase A or B. Isoinhibitor III, which was 
identical to II except that it lacked the amino terminal pyrrolidone carboxylic acid and 
the following glutamine residue, was also functionally indistinguishable from II (Hass et 
al., 1979a). The relative amount of each of three isoinhibitor families was estimated in 
extract of leaves, stems, sprout and tuber and it was demonstrated that very few 
differences in distribution could be found in the potato plant, although tuber contained 
the highest level. Furthermore, the three isoinhibitor families account for essentially all 
of the carboxypeptidase inhibitor activity in the potato tuber. However, PCI activity is 
found throughout the plant and thus the function of this peptide is presumably not 
tissue-specific (Hass et al., 1979b).  
TOMATO CARBOXYPEPTIDASE INHIBITORS 
In 1981 Hass and Hermodson published the sequence of a tomato carboxypeptidase 
inhibitor, but it was only in 1991 that Martineau et al. identified and characterized the 
cDNA clone of the tomato metallo carboxypeptidase inhibitor (TCMP-1) screening a 
Solanum lycopersicum cv UC82 ovary cDNA library. The clone contained an open reading 
frame coding for the 37 amino acids mature TCMP protein sequence identified, as well 
as an additional N-terminal sequence of 32 amino acids and an extension of 8 amino 
acids beyond the C-terminal of the published TCMP amino acid sequence (Hass and 
Hermodson, 1981). The N-terminal 32 amino acid region contains a typical hydrophobic 
signal sequence associated with transport of the nascent polypeptide across the rough 
endoplasmic reticulum (von Heijne, 1983). The polypeptide extension beyond the 
carboxy-terminus of the mature protein is also quite hydrophobic and it is similar to 
sequences found in a vacuolar protein of wheat germ (Raikhel and Wilkins, 1987) and in 
a barley lecithin (Lerner and Raikhel, 1989). For the C-terminal of barley lecithin it has 
been demonstrated its importance for the vacuolar sorting of the peptide (Wilkins et al., 
1990; Bednarek et al., 1990). Furthermore, PCI is accumulated in the vacuoles of potato 
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leaf cells (Holländer-Czytko et al., 1985); so the C-terminal of TCMP could be necessary 
for the vacuolar sorting. Alternatively, the C-terminal could inactivate the TCMP until the 
plant has reached a precise development stage or until the TCPI has reached its sub-
cellular localization.  
The function of TCMP-1 in plant is still not well understood, but it is considered, like 
other carboxypeptidase inhibitors, to be a potential protective agent against plant 
predators and pest by significantly lowering the digestibility of the plant organs where it 
is present (Bayés et al., 2006) 
Active TCMP-1 is present in tomato leaves in response to wounding and elicitors and it 
is synthesized with the same temporal induction as other wound inducible proteinase 
inhibitors that defend the plants against herbivores’ attacks (Díez-Díaz et al., 2004). 
TCMP-1 accumulation is highest in tomato ovary tissue during the period immediately 
after the opening of flowers (anthesis) (2%-5% of the total cellular protein) and is 
present at a very low level in ripe fruit (<0.4% of the total cellular protein) (Martineau et 
al., 1991) 
In 1989 the differential screening of a cDNA bank constructed from ripe tomato fruit 
mRNA (Solanum lycopersicum UC82) allowed the isolation of the cDNA clone 2A11. The 
open reading frame of 2A11 encoded a sulfur-rich polypeptide 96 amino acids in length 
(TCMP-2) (Pear et al., 1989). The putative protein sequence showed a very hydrophobic 
region at the N-terminal end which may indicate that the gene product is transported 
into a compartment other than the cytoplasm (Perlman and Halvorson, 1983).  
The gene encoding for TCMP-2 is fruit specific and shows no detectable expression in 
mRNA from roots, stems or leaves. The TCMP-2 message is approximately 1% of the 
poly(A+) mRNA in ripe tomato fruits (Pear et al., 1989). 
 
ANGIOGENESIS 
Angiogenesis, or neovascularisation, is the process of generating new capillary blood 
vessels. Blood vessel formation occurs both in physiologic and pathologic conditions, 
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and it supports tissue growth and organ function in development, physiology and 
disease. An insufficient supply of nutrient and oxygen prompts the formation of new 
vessels from the walls of existing vessels in a process termed angiogenic sprouting. The 
principal cells involved are endothelial cells, which line all blood vessels and constitute 
virtually the entirety of capillaries. Hypoxic tissues secrete growth factors and 
chemokines that stimulate the endothelial cells to escape from their stable location by 
breaking through the basement membrane. Once this is achieved, endothelial cells 
migrate towards the angiogenic stimuli and jointly coordinate sprouting, branching and 
new lumenized network formation, until supply meets demand and quiescence can be 
re-established (Fraisl et al., 2009).  
Once it is initiated by environmental growth factor signals, the sprouting process is 
spearheaded by leading endothelial tip cells (Gerhardt et al., 2003). In response to 
vascular endothelial growth factor-A (VEGF-A), these specialized endothelial cells 
situated at the tips of vascular sprout extend long filopodia that respond to extracellular 
VEGF-A gradients through tyrosine kinase and other receptors and lead to directed 
migration of tip cells. The endothelial cells that follow the tip cells, termed stalk cells, 
produce fewer filopodia and instead proliferate when stimulated with VEGF-A (Gerhardt 
et al., 2003). They also form the vascular lumen (Iruela-Arispe and Davis, 2009), and 
they establish adherens and tight junctions to maintain the integrity of the new sprout 
(Dejana et al., 2009) and to establish luminal/abluminal polarity, which, in turn, leads to 
basal lamina deposition and mural cell recruitment/attachment. It has been 
demonstrated that endothelial tip and stalk cells differ in their gene expression profile 
and that these differences are quantitative and most prominent at the mRNA level. 
(Claxton and Fruttiger, 2004; Siekmann and Lawson, 2007; Tammela et al., 2008). These 
quantitative differences in gene expression support the idea that tip and stalk cells have 
specialized functions during sprouting angiogenesis. Each new sprout eventually 
connects with adjacent sprouts via the tip cell establishing a simple vascular network. 
The vascular lumen is then established via formation of vacuoles, which eventually fuse 
with those of adjacent endothelial cells to generate a seamless tube with an intracellular 
lumen and thus establish flow in the new vascular loop (Blum et al., 2008; Leslie et al., 
2007). Establishment of flow and recruitment of basement membrane and mural cell 
contribute to the remodelling and maturation of the new vascular connection (Jain, 
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2003; Jones et al., 2006; Lucitti et al., 2007). Flow-dependent tissue oxygenation finally 
downregulates paracrine VEGF-A production, and thus helps establish a quiescent state 
for the new vessels.  
Not all connections remain stable, however, as extensive remodelling reshapes the 
primitive plexus (Fruttiger, 2007). Vascular network reorganization demonstrates the 
capacity to alter its branching pattern by means of alternative forms of nonsprouting 
angiogenesis (Kurz, 2000), for example by intussusceptions, i.e. the formation of 
transvascular tissue pillars (Burri and Tarek, 1990), or by the phenomenon of ‘pruning’, 
i.e. obliteration and removal of branches from a bifurcation (Baffert et al., 2006; Hughes 
and Chang-Ling, 2000). All these events are regulated by hemodynamic forces and 
crosstalk between the endothelial cells, mural cells, and the tissue environment (Djonov 
et al., 2002; Jain, 2003; Lucitti et al., 2007). 
What controls the specification of endothelial tip and stalk cells? How is tip cell 
migration and protrusive activity regulated? What controls the number of stalk cells and 
their proliferation? How do tip cells communicate during the formation of new 
connections? And what determines which connections will regress during pruning? All 
of these processes are tightly controlled by pro-angiogenic and anti-angiogenic factors, 
and are driven by a cocktail of growth factors and pro-angiogenic cytokine (Klagsbrun 
and D'Amore, 1991; Lee et al., 2005). The list of factors capable of eliciting an angiogenic 
response is steadily growing; some of these factors take a centre stage position, whereas 
others play more auxiliary roles (Risau, 1997). VEGF and its receptors play a critical 
roles in the processes of angiogenesis promoting endothelial cell differentiation, 
migration, and proliferation; controlling endothelial cell-cell junctions; suppressing 
apoptosis, and more. Many other pathways, including the epidermal growth factor 
receptor (EGFR), regulate the angiogenic response. Over the past few years, it has 
become clear that the EGFR signaling pathway plays a key role in coordinating multiple 
aspects of endothelial behaviour during vessel patterning and thus in shaping the 
formation and remodelling of the vascular network. For instance, VEGF can induce other 
pro-angiogenic factors, such as heparin-binding epidermal growth factor (HB-EGF) 
which promotes angiogenesis in endothelial cells via EGFR activation (Mehta and 
Besner, 2007). Furthermore, the angiotensin II-mediated cross-activation of EGFR is 
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responsible for neo-angiogenesis in endothelial cells and for the expression of VEGF 
(Fujiyama et al., 2001).  
ANGIOGENESIS IN CANCER 
As has been said before, angiogenesis is the formation of new blood vessels from pre-
existing vessels to form capillary networks. It is a fundamental event of physiological 
processes, like organogenesis, wound healing and muscle growth (Carmeliet, 2005) and 
involves a complex balance of positive and negative regulators, including VEGF which is 
one of the most important pro-angiogenic factor. 
Unfortunately, angiogenesis takes also place in pathological situations and it is a 
prerequisite for sustained growth of primary tumors and metastases. The angiogenic 
process in the tumor microenvironment involves the complex interplay of free 
angiogenic growth factors with their cognate receptors and endothelial cell activation, 
proliferation, and migration leading to a vascular remodelling. The VEGF family has been 
the most extensively studied among pro-angiogenic factors. (Epstein, 2007; Shibuya and 
Claesson-Welsh, 2006). The VEGF family includes 6 glycoproteins (VEGF-A to E and 
placental growth factor) and 3 tyrosine kinase receptors (VEGFR1 to 3). VEGF-A 
promotes angiogenesis through enhancement of permeability, activation, survival, 
migration, invasion, and proliferation of endothelial cells (Hicklin and Ellis, 2005). 
VEGFR1 and VEGFR2 mediate the effects of VEGF-A (Ferrara et al., 2003). Recent studies 
suggest that VEGF-A is the main ligand involved in tumor angiogenesis (Kim et al., 1993; 
Ferrara and Gerber, 2001; Ferrara, 2002). A direct effect has been shown of VEGF-A on 
tumor cell proliferation via a mechanism thought to involve the Akt/mTOR pathway 
(Trinh et al., 2009); VEGF-A regulates the invasiveness of cancer cells by altering the 
expression of matrix metalloproteinase-2 (Zhang et al., 2006). Moreover, the tumor cell 
and its supporting infiltrating macrophages and mesenchymal cells have been 
demonstrated to secrete VEGF-A (Liang et al., 2006), which contributes to increased 
tumor growth and metastasis. 
Angiogenesis and the molecular determinants of the angiogenic cascade have been 
characterized over the years, and it has emerged that their role raised great importance 
not only for tumors, but also for a number of non-oncological diseases, such as 
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rheumatoid arthritis (Szekanecz et al., 2009), psoriasis (Chua and Arbiser 2009), 
proliferative retinopathies (Sapieha et al., 2010), diabetic retinopathies (Crawford et al., 
2009) and age-related macular degeneration (Novak, 2006).  
ANGIOGENESIS AS THERAPEUTIC TARGET 
Being one of the hallmarks of cancer, anti-angiogenic therapy in cancer has become very 
popular. This idea was introduced 40 years ago by Folkman (Folkman, 1971), but even if 
specific angiogenic inhibitors have been discovered, challenges still exist in the clinical 
application of these inhibitors. The most impressive anti-cancer results today are with 
agents targeting VEGF/VEGF receptor (VEGFR) pathway. 
The most widely investigated anti-VEGF ligand agent is bevacizumab (BEV). BEV is a 
recombinant humanized monoclonal antibody that binds and neutralizes all biologically 
active isoforms of VEGF (Ferrara et al., 2004). BEV is now in clinical use and effective 
toward some types of cancer (Folkman, 2006). Other monoclonal antibodies directed 
against VEGF are in clinical trials.  
Besides VEGF-ligand-binding anti-angiogenic agents, there are VEGFR tyrosine kinase 
inhibitors. For example cediranib, a highly selective and potent oral tyrosine kinase 
inhibitor of VEGFR1, VEGFR2, VEGFR3 (Wedge et al., 2005) that is in phase I evaluation 
(van Cruijsen et al., 2010) or semaxinib, a tyrosine kinase inhibitor with activity against 
VEGFR2 that is able to reduce microvessel density and tumor growth in preclinical 
tumor model with high VEGF expression (Holtz et al., 2008).  
Despite these promising data, some combination trials have resulted in very 
disappointing results. The inhibitors have been seen to cause serious side effects (Elice 
et al., 2009; Daher and Yeh, 2008), and in a recent preclinical study of a therapy with 
metronomic paclitaxel in combination with the VEGFR2 inhibitors semaxinib, 
researchers found that those agents showed an additive effect in tumors with low VEGF 
expression, while they observed an antagonism in tumors with high VEGF expression 
(Holtz et al., 2008). These experiments suggest that a better knowledge of various 
molecular pathways implicated will help us to investigate the optimal combination 
partners.  
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In conclusion, anti-angiogenic treatment for cancer is looking very promising but it still 
requires the identification of new angiogenesis inhibitors with limited toxicity and a 
broader efficiency.  
 
EGF AND EGFR 
Human epidermal growth factor (EGF) is a 53 amino acids single-chain polypeptide (6 
kDa) that arises from the proteolytic cleavage of a large (1207 amino acids) integral 
membrane protein precursor (Carpenter and Cohen, 1990). This growth factor 
stimulates the proliferation of epithelial cells, inhibits gastric acid secretion, and is 
involved in wound healing. EGF is closely related structurally to transforming growth 
factor-alpha (TGF-), which bind to epidermal growth factor receptor (EGFR).  
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB 
family, which is composed of four closely related transmembrane tyrosine kinases: 
ErbB1 (EGFR), ErbB2 (HER2/neu), ErbB3 and ErbB4. These receptors can form both 
homo- and heterodimers in a manner that is dependent on the combination of receptors 
present, the stimulatory ligand, and the intracellular signaling pathway activated (Riese, 
1995). This allows them to affect, positively and negatively, a wide variety of cellular 
functions. 
The EGFR is composed of three regions: the extracellular ligand domain, a 
transmembrane region, and the intracellular protein tyrosine kinase domain (Ennis et 
al., 1991). There are a number of EGFR ligands, including EGF, TGF-, amphiregulin, 
heparin-binding EGF, betacellulin, and epiregulin (Salomon et al., 1995). Epidermal 
growth factor and TGF- are believed the most active EGFR ligands. These ligands 
function not only in a paracrine manner, but can also be secreted from tumor cells in an 
autocrine manner, thus enhancing their effects (Ruck and Paulie, 1998). Binding of 
ligands to the EGFR induces receptor dimerization, which leads to a cascade of cellular 
events. Upon EGFR dimerization, multiple residues of cytoplasmic kinase domain are 
autophosphorylated and several downstream adaptor protein are recruited under the 
plasma membrane, including GRB2, Shc or Dok-R. These adaptors mediate the activation 
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of different signal transduction pathways depending upon the type of ligand, levels of 
receptor expression and partner of EGFR dimerization. One of the most studied 
downstream pathways include the Ras/ERK signalling cascade (Figure 4 ).  
 
Figure 4. Schematic representation of EGFR downstream signaling pathway.(adapted from 
Bianco et al., 2007) 
 
The key player in EGFR-dependent Ras activation is the adaptor protein Grb2, which 
associates to the receptor, either directly or indirectly, by binding to EGFR linked and 
tyrosine phosphorylated Shc (Batzer et al., 1994; Lowenstein et al., 1992). It has been 
suggested that association of Shc with EGFR, which leads to its tyrosine phosphorylation 
and to the recruitment of Grb2, is the critical step in EGF-dependent induction of the 
Ras/MAPK pathway (Waters et al., 1996). Pre-associated with Grb2 is Sos, a guanine 
nucleotide exchange factor. Translocation of Grb2/Sos complex to the receptor in the 
plasma membrane facilitates the interaction of membrane-associated Ras with Sos, 
resulting in the activation of Ras small G protein. Activated Ras leads to the activation of 
the Raf-kinase that phosphorylates and activates the mitogen-activated protein kinases 
(MAPKs) (Voice et al., 1999; Marais and Marshall, 1996). MAPKs is a superfamily of 
protein serine-threonine kinases, which includes the extracellular signal regulated 
kinases (ERKs), the c-Jun terminal kinase (JNKs) also know as stress-activated protein 
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kinases (SAPKs) and p38-mitogen-activated protein kinases (Johnson et al., 2005). MAP 
kinases can translocate into the nucleus and phosphorylated transcription factors 
making them active inducing gene transcription, leading to increased levels of inhibitors 
of apoptosis proteins (IAPs) and anti-apoptotic Bcl-2 family members (Lin et al.,2002). 
Finally Erk1/2 kinases positively regulate cell proliferation by activating the major 
transcription factors associated with cell proliferation, such as c-Myc, and ribosomal 
subunit kinase (RSK) family isoforms (Murphy et al., 2002; Gavin and Nebreda, 1999).  
The transduction pathway primarily involved in the regulation of cell proliferation and 
apoptosis is represented by the PI3K/Akt pathway. The EGFR C-terminal intracellular 
domain provides a docking site for the p85 subunit of PI3K either directly or indirectly 
through binding to protein adaptors such as Grb2 (Stover et al., 1995). Upon activation, 
PI3K generates phosphatidyl-inositol-3,4,5-tris-phosphate (PIP3) which recruits and 
activates the serine-threonine kinase Akt. Phosphorylated Akt controls cell survival 
through phosphorylation of several downstream targets, such as apoptotic proteins of 
the Bcl-2 family (Song et al., 2005), transcription factors which, in turn, cause an 
increased transcription of anti-apoptotic genes (Song et al., 2005; Kane et al., 1999), and 
protein kinases or causing their inactivation, as in the case of Gsk-3 involved in the 
regulation of cell metabolism, or causing their activation, as for mTOR implicated in cell 
survival (Chan, 2004; Sun et al., 2005). Again, the final result is a decreased pro-
apoptotic gene expression and consequent increased cell survival.  
In addition to the Akt survival pathway, EGFR is able to regulate STATs pathway (Andl et 
al., 2004; Kloth et al., 2003). In fact, EGFR activation induces phosphorylation of STAT1, 
which in turn initiates formation of complexes, causing the translocation of STAT 
proteins to the nucleus and consequent regulation of gene expression and cell survival 
(Andl et al., 2004; Leaman et al., 1996).  
Additional biological responses of EGFR activation can result in proliferation of cancer 
cells with enhanced metastatic potential.  
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RELATIONSHIP AMONG EGFR, CANCER AND ANGIOGENESIS 
Tumor development and progression depend mainly on cellular changes like over-
expression of oncogenic tyrosine kinase receptors (Hanahan and Weinberg, 2000). The 
activity of the EGFR, that is a tyrosine kinase receptor of the ErbB family, is abnormally 
elevated in most human solid tumors and has been associated with progression and 
poor prognosis (Salomon et al., 1995; Brabender et al., 2001). Various mechanisms are 
likely to be involved in aberrant EGFR signaling: production of EGFR-ligands by tumor 
cells or stromal cells in their environment, high expression of EGFR associated with 
enhanced sensitivity for EGF-like ligands, and constitutively active EGFR mutations that 
lead to ligand-independent activation of the receptor (Hirata et al., 2002). Up-regulated 
EGFR signaling is known to initiate a cascade of events leading to cell proliferation, 
migration, invasion (Mendelsohn and Dinney, 2001) and blocking of apoptosis (Kulik et 
al., 1997). So, EGFR is expected to be a valuable molecular target for effective anti-cancer 
agents. In vitro experiments with therapeutic agents against EGFR induce anti-
proliferative effects in tumor cells cultured. This most frequently results in cytostatic 
effects, more than cytoreduction and apoptosis. In contrast, in several in vivo models 
anti-EGFR therapy frequently induces tumor regression, which may not be solely 
explained by inhibition of the molecular target. (Hanahan and Folkman, 1996). This 
discrepancy suggests that EGFR signaling affects both biological characteristics of the 
tumor cell and tumor-host interactions like angiogenesis. Angiogenesis is essential for 
tumor growth and metastasis formation and the VEGF is a key stimulator of this process. 
Petit et al. reported in 1997 that the oncogeneity of the EGFR might partially be 
mediated through promotion of angiogenesis by up-regulating VEGF (Petit et al., 1997). 
Since then there has been growing evidence that stimulation or inhibition of EGFR also 
has significant consequences for tumor-induced angiogenesis (Yen et al., 2002; Ellis, 
2004). Direct EGFR angiogenic effects have been demonstrated by Hirata and colleagues 
(Hirata et al., 2002). It has been shown that human microvascular endothelial cells 
express EGFR (ErbB1). Stimulation of these cells with EGF or TGF- induced tube 
formation. For a great variety of tumor cells it has been demonstrated that activation of 
the EGFR pathway increases the production of angiogenic molecules. EGF stimulation of 
glioma cells consistently increased the production of VEGF by these cells (Goldman et al., 
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1993); EGFR and HER-2/neu have been identified as important regulators of gastric 
cancer growth and angiogenesis, which in part involves up-regulation of VEGF-A 
(Allgayer et al., 2000). In a bladder carcinoma cell line, EGF increased the production of 
VEGF and bFGF (Perrotte et al., 1999). In gastric and pancreatic cell lines, EGF 
stimulation also caused an enhanced production of neurophilin-1, a co-receptor of 
VEGFR2, increasing the affinity of specific isoforms of VEGF to VEGFR2 (Parikh et al., 
2003). Under EGF stimulation A431 cells (human epithelial carcinoma cell line), which 
express high levels of EGFR, produce VEGF and IL-8, both positive regulators of 
angiogenesis that stimulate endothelial cells growth through paracrine mechanisms 
(Hirata et al., 2002). Furthermore, EGF induces VEGF in many cell lines through 
increased VEGF mRNA transcription (Maity et al., 2000; Pore et al., 2003). EGFR 
stimulation activates many downstream signaling pathways including the PI3K/Akt 
pathway (Dutta and Maity, 2007). Activated Akt increases expression of a key 
transcription factor, hypoxia-inducible factor-1 (HIF-1) (Zhong et al., 2000; Zundel et 
al., 2000). One of the many transcriptional targets of HIF-1 is the VEGF gene. 
Conversely, pharmacological inhibition of EGFR can decrease VEGF expression and 
consequently angiogenesis in many tumor type (Ciardiello et al., 2001; Huang et al., 
2002; Perrotte et al., 1999; Petit et al., 1997; Pore et al., 2006). 
Based on this evidence, it is clear that there is a connection between EGFR signaling and 
VEGF expression, which means a tight correlation between EGFR and angiogenesis. 
EGFR AS THERAPEUTIC TARGET OF CANCER ANGIOGENESIS AND 
TUMOR GROWTH 
In cancer anti-angiogenic therapy has become very popular, but only few VEGFR 
inhibitors are now in clinical use because most of them seem to cause serious side 
effects (Elice et al., 2009; Daher and Yeh, 2008). Identification of new angiogenesis 
inhibitors with limited toxicity and a broader efficiency is needed and the idea is that 
agents inhibiting new vessel formation and blood supply can have anti-cancer effects. 
EGFR and VEGFR share common downstream signaling pathway and several preclinical 
studies have provided evidence for either direct or indirect angiogenic effects of EGFR 
signaling. Multiple therapeutic strategies have been developed to target EGFR, including 
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monoclonal antibodies, tyrosine kinase inhibitors, ligand-toxin conjugates, antagonist of 
EGF/EGFR and antisense oligonucleotides. At this time there is no evidence showing 
superiority of one approach over another.  
Anti-EGFR monoclonal antibody (MAbs) binds to the extracellular domain of the EGFR, 
which interferes with the binding of endogenous ligands, most importantly, EGF and 
TGF-. After binding, the receptor-antibody complex is internalized, preventing receptor 
dimerization and autophosphorylation. A variety of anti-EGFR MAbs have undergone 
significant preclinical testing and a number are in clinical testing in a variety of tumor 
types. For example cetuximab reduces the production of VEGF and IL-8 by human 
transitional, pancreatic, colon and epidermoid (A431) cancer cells in vitro (Petit et al., 
1997; Perrotte et al., 1999; Bruns et al., 2000; Ciardiello et al., 2000), whereas antibodies 
directed against the extracellular domain of ErbB2 resulted in a dose-dependent down-
regulation of VEGF production by an ErbB2 positive breast cancer cell line (Petit et al., 
1997).  
Tyrosine kinase inhibitors interfere with EGFR functioning after ligand binding by 
directly inhibiting tyrosine phosphorylation (Noonberg and Benz, 2000). Erlotinb and 
gefitinib, are the tyrosine kinase inhibitors most advanced in clinical development. 
Erlotinb treatment of various human tumor cells in vitro and mice bearing xenografts in 
vivo led to decreased HIF-1 alpha and VEGF expression (Pore et al., 2006; Cerniglia et al., 
2009). Hirata and colleagues has demonstrated that treatment of human microvascular 
endothelial cells with gefitinib inhibited EGF-induced migration and tube formation 
(Hirata et al., 2002).  
Epidermal growth factor receptor ligand can be attached or conjugated to toxins, such as 
ricin or Pseudomonas exotoxin, to form ligand conjugates (Noonberg and Benz, 2000). 
These receptor-targeted strategies bind exclusively to the EGFR and allow lethal toxin to 
enter the cell and result in cell death, but this approach is not as widely studied as the 
anti-EGFR MAbs. 
EGF antagonists can act as anti-angiogenic factors and as anti tumor-growth: a synthetic 
murine EGF is capable of blocking the angiogenic stimulus of native murine EGF in the 
chick VIM model (Nelson et al., 1991); treatments with chimeric fusion protein that 
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contain granzyme B fused with TGF- resulted in selective and rapid tumor cell killing 
(Dälken et al., 2006); the EGF antagonist action of PCI as inhibitor of cancer growth has 
been the first reported example of an antagonistic analogue of human EGF (Blanco-
Aparicio et al., 1998). Another promising molecule is Argos, a natural secreted 
antagonist of EGFR identified in Drosophila (Freeman et al., 1992). Argos functions by 
directly binding and sequestrating growth factor ligands that activate EGFR. It mimics 
EGFR by using a bipartite binding surface to entrap EGF (Klein et al., 2008).  
EGFR or TGF- antisense oligonucleotides that bind to DNA or RNA have been employed 
to block the protein synthesis within the cell (Moroni et al., 1992). Antisense therapies 
are in the very early stages of testing, and their clinical utility for cancer treatment is still 
to be discovered.  
POTATO CARBOXYPEPTIDASE INHBITOR AS EGF ANTAGONIST 
Much effort is currently being devoted to finding new molecules that target transduction 
pathway (Levitzki, 1996), including antagonists that bind to growth factor receptors 
without activating them (Zumkeller and Schofield 1995; Groenen et al., 1994; Baselga 
and Mendelsohn, 1994). The potato carboxypeptidase inhibitor (PCI) is the first 
reported antagonistic analogue of human EGF that is able to bind to EGFR without 
eliciting the activation of the receptor (Blanco-Aparicio et al., 1998). Blanco-Aparicio et 
al. demonstrated that PCI, in micromolar concentration, not only binds to EGFR 
competing with EGF, but it also inhibits all the steps in ligand-induced activation of 
EGFR by EGF: receptor dimerization, induction of tyrosine kinase activity and tyrosine 
transphosphorylation. Moreover, they show that PCI was able to inhibit the 
development of human adenocarcinoma tumors transplantated into nude mice without 
inducing any observable toxic side effects and that PCI has a long lasting inhibitory effect 
on the in vitro growth of pancreatic adenocarcinoma cell lines, which is maintained even 
when it is removed from the culture medium. Blanco-Aparicio et al. surmise that the 
antiproliferative effect of PCI is probably due to the fact that it is an EGF antagonist and 
that the effect of PCI on tumor growth could be attributable to its special topology.  
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A I M  O F  T H E  R E S E A R C H   
In recent years, several natural products have received great attention for their potential use 
in cancer prevention thanks to their various benefits, noticeably little or no toxicity and side 
effects, low cost and human acceptance. Several studies highlighted tomato as an important 
health-promoting fruit, rich in carotenoid compounds as well as vitamins, minerals, dietary 
fiber and phenols. The anti-tumoral protective role of tomato has been principally ascribed to 
its high content of antioxidant molecules, especially lycopene. However, just what is the active 
principle(s) is not completely clear yet, but the research has almost completely focused on 
secondary metabolites, whereas other molecules, for instance peptides and proteins present 
in tomato fruit, have received little attention. Anti-angiogenic treatment is a very effective 
strategy in cancer therapy although the identification of new angiogenesis inhibitors with 
limited toxicity and a broader efficiency are needed. Among several targets, inhibition of EGFR 
seems to represent a novel and promising approach.  
This research aims to investigate the biological action on human cells of two tomato 
miniproteins which are normal components of our diet. The motivation for this research 
stems from the discovery that two tomato cystine-knot miniproteins (TCMPs), one expressed 
in the flower (TCMP-1) and the other in the mature fruit (TCMP-2), are similar in sequence 
and structure to a potato carboxypeptidase inhibitor (PCI) that has been shown to have anti-
cancer properties. PCI, acting as EGF antagonist, inhibits tumor cell growth (Blanco-Aparicio 
et al., 1998). Since EGF is one of the signalling molecules participating in the formation of new 
vessels, we must ask ourselves whether, TCMP-1 and TCMP-2, that can bind to the surface of 
human cells (endothelial cells, carcinoma cells; Cavallini, 2005), could also exert anti-
angiogenic activity with limited cell toxicity. 
The first part of the project was dedicated to the production of the recombinant tomato 
miniproteins TCMP-1 and TCMP-2 and the purification of the TCMP-2 from tomato fruit. The 
second part concerned the evaluation of the biological action of TCMP proteins on human 
cells, focusing on angiogenesis and on the investigation of the signal transduction pathways 
related to EGFR. The last part regarded the creation of chimeric gene constructs for tomato 
plant transformation aimed at increasing the content of TCMPs in mature tomato fruits. 
Materials and Methods 
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M A T E R I A L S  A N D  M E T H O D S  
PLANT MATERIAL 
UC82 tomato plants were grown in a greenhouse under a 10/14 hours light/dark cycle 
at 24°C and 18°C, respectively. UC82 is a typical cultivar used by the processing industry. 
Commercially available ripe tomatoes were used for the purification of fruit TCMPs. 
NORTHERN BLOT ANALYSIS 
Total RNA was isolated with Trizol (Invitrogen Ltd, Paisley, UK) and 20 g of total RNA 
were separated on 1% agarose-formaldehyde denaturing gels. The gels were blotted 
overnight on Hybond N+ membrane (Amersham Biosciences, GE Healthcare Europe 
GmbH, Munich, Germany) in 10X SSC. The DNA probes were labeled with (-32P)-dCTP 
using ‘Ready to go DNA labeling beads (-dCTP)’ (Amersham Biosciences, GE Healthcare 
Europe GmbH, Munich, Germany). Unincorporated nucleotides were removed with 
Probe G-50 micro columns (Amersham Biosciences, GE Healthcare Europe GmbH, 
Munich, Germany). The membranes were hybridised overnight at 42°C in ULTRAhyb 
buffer (Applied Biosystem/Ambion, Austin, TX, USA). 106 cpm ml-1 of labelled probe 
were added to the hybridization buffer. The membranes were washed 2 times in 2X 
SSC/0.1% SDS for 5 minutes and 2 times in 0.1X SSC/0.1% SDS for 15 minutes at 42°C. 
Autoradiography was then performed using Kodak X-AR5 film. For TCMP-1, TCMP-2 and 
actin mRNAs analysis, the DNA probes were obtained by PCR using the following 
primers:  
TCMP-1:  
forward      5’-ATGGCACAAAAATTTACTATCCTTTTCACC-3’; 
reverse       5’-GATTACATATCACACCCTAATGACATAATT-3’;  
TCMP-2: 
forward     5’-TGAAGCTACTTCCCACAAATATTTTG-3’; 
reverse      5’-TCCCTTTATTCATATTCTTCACACC-3’;  
Actin: 
forward     5’-CCCGTTCAGCAGTGGTGGT-3’; 
reverse      5’-TACGAGGGTTATGCTTTGCC-3’. 
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CLONING AND EXPRESSION OF RECOMBINANT TCMP-1 AND TCMP-2 
The DNA sequences corresponding to the coding regions of the mature TCMP-1 and the 
putative 44 amino acids of mature TCMP-2 protein were amplified by PCR using cDNAs 
as template. The upstream and downstream primers were designed in order to 
introduce at the 5′-terminal a restriction site for NdeI and a His6-tag sequence and at the 
3′-terminal end two stop codons and a restriction site for BamHI. The primers 
sequences are listed as follow:  
TCMP-1 forward:  
5′-GGGAATTCCATATGCATCATCATCATCATCACCAGCAATATGATCCAGTTTGTCACAAAC 
CT-3′;  
 
TCMP-1 reverse:  
5′-CGGGATCCTTATTAAACATAGGGCCCACATGTCCCCGCGAA-3′;  
 
TCMP-2 forward:  
5′-TCCTGTAACCATATGCATCATCATCATCATCACACAAATATTTTGGGACTTTGTAACGAA 
CCT-3′;  
 
TCMP-2 reverse:  
5′-TGGGATCCTTATTAAGGCAACAGGTTGCATGTACGGTATGT-3′  
 
(sequences for restriction sites are reported in italics, the His6-tag sequence is in bold 
and sequences for stop codons are underlined). PCR products were subcloned using 
pGEM®-T Easy Vector System, (Promega GmbH, Mannheim, Germany) and checked by 
sequencing. The PCR products were double digested with NdeI-BamHI and the resulting 
fragments were ligated into pET12b vector (Novagen, Merck Chemicals Ltd, Nottingham, 
UK). The recombinant plasmids were named pET12-T1 (for TCMP-1) and pET12-T2 (for 
TCMP-2). Origami B and BL21 pLysS (Novagen, Merck Chemicals Ltd, Nottingham, UK) 
Escherichia coli (DE3) competent cells were transformed with pET12-T1 and pET12-T2 
plasmids, respectively. For the TCMP-1, the expression of recombinant protein was 
induced by 0.7 mM of isopropyl--D-thiogalactopyranoside (IPTG) at 24°C for 5 hours. 
For the TCMP-2, the expression of the recombinant protein was induced by 0.4 mM IPTG 
at 37°C for 5 hours. 
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CLONING AND EXPRESSION OF RECOMBINANT TCMP-1 AND TCMP-2 AS 
FUSION PROTEINS 
The DNA sequences corresponding to the coding regions of the mature TCMP-1 and the 
putative 44 amino acids of mature TCMP-2 protein were amplified by PCR using cDNAs 
as template. The upstream and downstream primers were designed in order to 
introduce at the 5′-terminal a restriction site for SmaI and nucleotides to reform the 
thrombin cleavage site and at the 3′-terminal end two stop codons and a restriction site 
for BamHI. The primers sequences are listed as follow:  
TCMP-1 forward: 
5′-CCCGGGGCAGCCAGCAATATGATCCAGTTTGTCACAAACCT-3′;  
 
TCMP-1 reverse:  
5′-CGGGATCCTTATTAAACATAGGGCCCACATGTCCCCGCGAA-3′;  
 
TCMP-2 forward:  
5′-CCCGGGGCAGCACAAATATTTTGGGACTTTGTAACGAACCT-3′;  
 
TCMP-2 reverse:  
5′-TGGGATCCTTATTAAGGCAACAGGTTGCATGTACGGTATGT-3′  
 
(sequences for restriction sites are reported in italics, nucleotides to reform the 
thrombin cleavage site are in bold and sequences for stop codons are underlined). PCR 
products were subcloned using pGEM®-T Easy Vector System, (Promega GmbH, 
Mannheim, Germany) and checked by sequencing. The PCR products were double 
digested with SmaI-BamHI and the resulting fragments were ligated into pET43.1a 
vector (Novagen, Merck Chemicals Ltd, Nottingham, UK). The pET43.1a vector is 
designed for cloning and high-level expression of peptide sequences fused with the 491 
amino acids Nus•Tag™ protein. Vector encoded sequence can be completely removed 
when cloning into the SmaI site by cleaving the Nus•Tag fusion protein with thrombin. 
The recombinant plasmids were named pET43-T1 (for TCMP-1) and pET43-T2 (for 
TCMP-2). BL21, Origami B and BL21 pLysS (Novagen, Merck Chemicals Ltd, Nottingham, 
UK) Escherichia coli (DE3) competent cells were transformed with pET43-T1 and 
pET43-T2 plasmids. The expression of recombinant protein was induced by 0.4 mM of 
isopropyl--D-thiogalactopyranoside (IPTG) at 37°C for 5 hours. 
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CLONING AND EXPRESSION OF RECOMBINANT TCMP-2 IN 
PERIPLASMIC SPACE 
The DNA sequences corresponding to the coding regions of the putative 44 amino acids 
of mature TCMP-2 protein were amplified by PCR using cDNAs as template. The 
upstream and downstream primers were designed in order to introduce at the 5′-
terminal a restriction site for SalI, a His6-tag sequence and a enterokinase cleavage site 
sequence and at the 3′-terminal end two stop codons and a restriction site for BamHI. 
The primers sequences are listed as follow:  
TCMP-2 forward:  
5′-GTCGACGCATCATCATCATCATCACGACGACGACGACAAGACAAATATTTTGGGACTT 
TGTAACGAACCT-3′;  
 
TCMP-2 reverse:  
5′-TGGGATCCTTATTAAGGCAACAGGTTGCATGTACGGTATGT-3′  
 
(sequences for restriction sites are reported in italics, the His6-tag sequence is in bold, 
the enterokinase cleavage site is double underlined and sequences for stop codons are 
underlined). PCR products were subcloned using pGEM®-T Easy Vector System and 
checked by sequencing. The PCR products were double digested with SalI-BamHI and 
the resulting fragments were ligated into pET12b vector. The recombinant plasmid was 
named pET12s-T2 (for TCMP-2). BL21, Origami B and BL21 pLysS Escherichia coli (DE3) 
competent cells were transformed with pET12s-T2 plasmid. The expression of 
recombinant protein was induced by 0.4 mM of isopropyl--D-thiogalactopyranoside 
(IPTG) at 37°C for 5 hours. 
RECOMBINANT TCMP-1 AND TCMP-2 PRODUCTION CHECK 
To verify the production and localisation of TCMP-1 and TCMP-2 recombinant proteins, 
cell cultures were centrifuged at 10000 xg for 10 minutes at 4°C. The cell pellets were 
resuspended in lysis buffer (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol). Cell 
suspensions were lysed by lysozyme (0.1 mg ml-1), by repeated freeze and thawing (3 
times) and by mild sonication. DNase (20 g ml-1) was also added to cell suspensions in 
order to decrease the viscosity of the samples. The soluble and insoluble fraction were 
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recovered by centrifugation at 16000 xg for 20 minutes at 4°C and analyzed by gel 
electrophoresis.  
PURIFICATION OF RECOMBINANT TCMP-1 AND TCMP-2 
For the isolation of TCMP-1 and TCMP-2 recombinant proteins, cell cultures were 
centrifuged at 10000 xg for 10 minutes at 4°C. The cell pellets were resuspended in lysis 
buffer (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol). Cell suspensions were lysed 
by lysozyme (0.1 mg ml-1), by repeated freeze thawing (3 times) and by mild sonication. 
DNase (20 g ml-1) was also added to cell suspensions in order to decrease the viscosity 
of the samples. The insoluble fraction, containing aggregated target protein (inclusion 
bodies) were recovered by centrifugation at 16000 xg for 20 minutes at 4°C. The pellets 
were washed three times with wash buffer (20 mM Tris-HCl pH 8.0, 50 mM NaCl, 50 mM 
2-mercaptoethanol, 5 mM EDTA, 2% Triton). Two protocols were then applied. First, 
inclusion bodies were resuspended in the solubilisation buffer (20 mM Tris-HCl pH 8.0, 
50 mM NaCl, 6 M guanidine hydrochloride, 50 mM -mercaptoethanol) for 1 hour and 
centrifuged 3000 xg for 10 minutes at room temperature. Denaturized inclusion bodies 
were loaded on a Ni2+-loaded HiTrap Chelating column (Amersham Biosciences, GE 
Healthcare Europe GmbH, Munich, Germany) and recombinant proteins (His-tagged) 
were affinity attached. Renaturation of the TCMPs occurred in column with a decreasing 
gradient (0.1 ml min-1) of guanidine hydrochloride, from 6 M to 0 M, and 2-
mercaptoethanol, from 50 mM to 5 mM. Renaturated proteins were then eluted and the 
fractions were loaded on a polyacrylamide gel and stained. Fractions containing the 
miniprotein of interest were pooled, dialyzed and concentrated with Amicon stirred 
cells with a membrane 1 kDa cut off (Ultrafiltration Membranes, Millipore).  
In the second protocol applied, inclusion bodies were resuspended in the solubilisation 
buffer (20 mM Tris-HCl pH 8.5, 6 M guanidine hydrochloride, 30 mM DTT) for 5 hours 
and then centrifuged 3000 xg for 10 minutes at room temperature. The solution was 
desalted with PD-10 column (Amersham Biosciences, GE Healthcare Europe GmbH, 
Munich, Germany) versus 0.1 M Tris-HCl pH 8.5 and then dialyzed overnight at 4°C in 
refolding buffer (0.1 M Tris-HCl pH 8.0, 4 mM cystine, 2 mM cysteine). After dialysis the 
sample was centrifuged 3000 xg for 10 minutes at room temperature, desalted with PD-
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10 column to eliminate cystine and cysteine and 10 mM imidazole was added. 
Recombinant proteins (His-tagged) were affinity purified using Ni2+-loaded HiTrap 
Chelating column. The eluted fractions were loaded on a polyacrylamide gel and stained. 
Fractions containing the miniprotein of interest were pooled, desalted with PD-10 
column to eliminate imidazole, filtrated with Centricon centrifugal filter 10000 MW 
(Millipore, Billerica, MA) and concentrated with Centricon centrifugal filter 3000 MW 
(Millipore, Billerica, MA). Polymyxin B (Aerosporin) (Sigma-Aldrich) was added at 10 g 
ml-1 to eliminate any contaminating endotoxins. This material was used in all 
subsequent experiments. 
PURIFICATION OF TCMPS FROM TOMATO 
Ripe tomatoes were peeled, and after seed removal homogenized with 1 ml g-1 of 
extraction buffer (30 mM Tris-HCl pH 8.2, 50 mM KCl, 1 mM EDTA, 5 mM 2-
mercaptoethanol, 0.19% EGTA, 0.5% Tween-20, 0.1% PVPP and protease inhibitors 
cocktail). The homogenate was centrifuged at 12000 xg for 20 minutes at 4°C and the 
supernatant was collected. Subsequent centrifugal filtration steps with Centricon 30000 
and Centricon 10000 were performed in order to clarify the homogenate. The 
homogenate were concentrated with Centricon 3000 and centrifuged 12000 xg for 20 
min at 4°C to eliminate debries before loading on chromatographic column. TCMP was 
affinity purified from total extract using either IgG antibodies or carboxypeptidase A 
(CPA), which were previously immobilised on columns, adopting the AminoLink Plus 
Immobilization Kit (Thermo Scientific-Pierce Protein Research Products, Rockford, IL). 
NMR SPECTROSCOPY 
TCMPs samples (6 mg ml-1) were prepared in 20 mM sodium phosphate buffer, pH 7.6, 
containing 10% D2O. The measurements were performed with a Bruker DRX 500 
spectrometer, operating at 500.13 MHz proton Larmor frequency, equipped with a triple 
resonance probe head, incorporating gradients in the z-axis. The measurement 
temperature was 25C. Pulse programs from the standard Bruker library (Topspin 1.3) 
were used. After dissolving the sample, the spectra were run with 128 scans, 16384 data 
points and relaxation delay of 2 seconds. Presaturation was used to suppress the 
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residual 1H2O signal. The data were Fourier-transformed and analysed using standard 
Bruker software. 
CARBOXYPEPTIDASE INHIBITION ASSAY 
Inhibition of carboxypeptidase activity was assayed using 28 nM bovine CPA and 1 mM 
hippuryl-L-phenylalanine (Sigma-Aldrich, St. Louis, MO) as substrates. Assays were 
performed according to Hass et al. (1981b), monitoring the substrate hydrolysis at 254 
nm in 20 mM Tris-HCl buffer (pH 7.5) containing 0.5 M NaCl. 
HUMAN CELL CULTURE  
Human Umbilical Vein Endothelial Cells (HUVECs) (Clonetics, Lonza, Basel, Switzerland) 
were plated on a 25 cm2 flask coated with bovine fibronectin (Sigma-Aldrich, St. Louis, 
MO). Cells were maintained on endothelial growth media (EGM-2) supplemented with 
EGM-2 Single Quots (Clonetics, Lonza, Basel, Switzerland) at 37°C and 5% CO2 in a 
humidified atmosphere.  
A431 cells were plated on a 25 cm2 flask. Cells were maintained on RPMI 1640 medium 
in presence of 10% fetal bovine serum and 50 g ml-1 gentamicin (Sigma-Aldrich, St. 
Louis, MO) at 37°C and 5% CO2 in a humidified atmosphere. For all applications, HUVEC 
and A431 cells were used from second to fourth passages. 
IN VITRO CAPILLARY FORMATION OF HUVEC PLATED ON MATRIGEL 
The assessment of in vitro capillary formation was performed using Matrigel Basement 
Membrane Matrix (BD Biosciences, San Jose, CA). The wells of 24-well plates were 
coated with Matrigel under sterile conditions. After gelification of the Matrigel 
suspension (300 l per well) for 1 hour at 37°C, 4x104 HUVEC were plated in each well 
and incubated 24 hours at 37°C and 5% CO2 in a humidified atmosphere in 0.7 ml of 
EGM-2 complete medium with or without TCMPs (100 and 200 nM) or AG1478 (500 
nM). Cells were photographed using a phase contrast microscope (Olympus CK2) 
coupled with D-100 Nikon digital camera. Tube formation was quantified by measuring 
the length of tube-like structures with the image-processing software ImageJ 
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(http://rsb.info.nih.gov/ij/). For each sample the tube length was measured in triplicate, 
for each replicate 3 fields (2.00x1.33 mm) per well were analysed.  
CELL VIABILITY ASSAYS  
Cell viability assay was performed using the WST-8 (MTT) Cell Proliferation Assay Kit 
(Cayman Chemical Company, Ann Arbor, MI), AnnexinV-FITC Apoptosis Detection kit 
(Bender MedSystem, Wien) and trypan blue test. For MTT assay, HUVECs either treated 
or not treated with experimental compounds were seeded, at a density of 1x104 
cells/well, in a 96-well plate. After 24 and 48 hours of growth, cell viability was 
evaluated. Each treatment was performed in triplicate according to manufacturer’s 
instructions. 
The percentage of apoptotic cells treated or not with TCMPs was determined using 
AnnexinV-FITC assay. The method was performed according to the manufacturer’s 
recommendations. HUVECs either treated or not treated with experimental compounds 
were seeded, at a density of 3x104 cells/well, in a 6-well plate. After 48 hours of growth, 
cells were stained with annexinV, which binds phosphatidylserine, and then they were 
stained with propidium, which is a DNA intercalating agent. Stained cells, at least 10000 
events, were acquired on a FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA) 
and analyzed with the use of FlowJo software (TreeStar, Ashland, USA). 
For trypan blue test, HUVECs were seeded, at a density of 48x103 cells/well, in 6-well 
plates. EGM-2 Single Quots and recombinant peptides were added to the endothelial 
growth medium. After 48 hours of cultivation, cells were treated with trypsin, collected 
and resuspended in 0.5 ml of serum-free culture medium. 0.1 ml of 0.4% trypan blue 
(Sigma-Aldrich, St. Louis, MO) was added to cell suspension and mixed thoroughly. After 
5 minutes of incubation at room temperature, trypan blue/cell mixture was applied to a 
hemocytometer and placed under a Olympus CK2 microscope (100X). The unstained 
(viable) and blue stained (non-viable) cells were counted.  
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CELL PROLIFERATION ASSAYS  
Cell proliferation was quantified with 5-ethynyl-2’-deoxyuridine (EdU; Click-iT™ EdU 
Alexa Fluor Cell Proliferation Assay kit, Invitrogen Ltd, Paisley, UK). EdU is a nucleotide 
analogue of thymidine that is incorporated into DNA during active DNA synthesis. 
HUVECs were seeded, at a density of 3x104 cells/well, in a 6-well plate coated with 
bovine fibronectin in culture medium with or without the recombinant TCMP-2 (200 
nM) and 10 M EdU. After 48 hours cells were detached and washed once with 
phosphate buffer before being fixed and permeabilized according to the manufacturer’s 
protocol. Stained cells, at least 10000 events, were acquired on a FACSCalibur™ flow 
cytometer (BD Biosciences, San Jose, CA) and analyzed with the use of FlowJo software 
(TreeStar, Ashland, USA).  
Cell proliferation was also measured by counting the cell numbers. HUVECs were 
seeded, at a density of 3x104 cells/well, in a 6-well plate coated with bovine fibronectin 
in culture medium containing the recombinant TCMP-2 (200 nM). After 24, 48, 72 and 
96 hours of cultivation, cells were counted in Neubauer chamber using optical 
microscope Olympus CK2 (100X). 
CELL MIGRATION WOUND ASSAYS  
HUVEC were prepared in a single cell suspension. Cells (1x104) were seeded onto a 24-
well culture plate and then cultured to at least 95% confluence. Monolayer cells were 
washed three times with phosphate-buffered saline. A wound was created in the cells’ 
monolayer with a 10- l micropipette tip and photographed at a magnification of 100X. 
Monolayer cells with wound were cultured in serum-free medium for another 24 h with 
or without stimuli and then photographed at the same position. Cells were treated with 
different concentrations of TCMPs alone or in combination with 5 ng ml-1 EGF 
(PeproTech, London, UK) or with the specific EGFR inhibitor AG1478 (Calbiochem, 
Gibbstown, NJ) (500 nM). The area of the cell wounds was calculated using the image-
processing software ImageJ. Results are expressed as the mean (± SD). 
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SDS-PAGE AND WESTERN BLOTTING ASSAYS 
For TCMPs electrophoretic analyses, protein samples were loaded on 15% Tris-Tricine 
SDS-polyacrylamide gel (PAGE) followed by Coomassie Blue or Silver nitrate staining.  
For MAPK signaling pathway analyses, HUVEC and A431 cell lines were treated with 
different concentrations of TCMPs alone or in combination with 5 ng ml-1 EGF or with 
the specific EGFR inhibitor AG1478 (500 nM). Cells were homogenized using different 
methods to find the optimal condition for each target protein (EGFR, ERK1/2, Akt): 1) 
lysed with a hot lysis buffer containing 4% SDS, 20% glycerol, 100 mM Tris-HCl pH 6.8, 
boiled for 3 minutes, mildly sonicated, centrifuged 1 minute at 16000 xg at room 
temperature and recovered the supernatant; 2) lysed with CelLytic M (Sigma-Aldrich, St. 
Louis, MO), transferred in ice for 1 hour, centrifuged 10 min 16000 xg at 4°C then 
supernatant was recovered; 3) lysed with a lysis buffer containing 2% SDS, 10% 
glycerol, 50 mM Tris-HCl pH 6.8, 100 mM DTT, mildly sonicated, centrifuged 10 minute 
at 16000 xg at room temperature and recovered the supernatant; 4) lysed with a cold 
lysis buffer containing 50 mM Tris-HCl pH 7.4, 5 mM MgCl2, 150 mM NaCl, 0.1% SDS, 1% 
Triton, 10 μg ml-1 APMSF, 0.5 μg ml-1 leupeptin, 0,7 μg ml-1 pepstatin, 50 mM NaF, 1 mM 
Na3VO4, 5 mM sodium pyrophosphate, 10 mM sodium--glycerolphosphate, 0.5 mM 
EDTA and 0.5% sodium deoxycholate, protease inhibitor cocktail (Sigma-Aldrich, St. 
Louis, MO). 
Supernatants were separated by 7.5% or 10% polyacrylamide gel electrophoresis (Tris-
Glycine SDS-PAGE) and blotted onto a PVDF membrane (Millipore). 
The level of total and phosphorylated EGFR was detected using EGFR and phospho-
EGFR Tyr1173 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), respectively. The 
level of total and phosphorylated ERK1/2 was detected using ERK1/2 and phospho-
ERK1/2 antibodies (Cell Signaling Technology, Danvers, MA), respectively. The level of 
total and phosphorylated Akt was detected using Akt and phospho-Akt antibodies (Cell 
Signaling Technology, Danvers, MA), respectively. Blots were developed using 
chemiluminescent substrate Lite A Blot Plus (Euroclone S.p.A., Siziano, Italy) using 
horseradish peroxidase (HRP)-conjugated secondary antibodies. The intensity of the 
chemiluminescence response was measured by scanning the films by GS710 
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densitometer (Bio-Rad) and processing the image with the Quantity One software 
Version 4.4 (BioRad). The density of proteins was expressed as absorbance (OD mm-2). 
GENE CONSTRUCTS FOR TCMP-1 EXPRESSION IN TOMATO FRUIT  
DNA fragments corresponding to the coding sequence for TCMP-1 precursor (77 amino 
acids; GenBank accession X59282), TCMP-1 mature miniprotein (37 amino acids) and 
beta-glucuronidase (GUS; as control) were PCR amplified and sub-cloned in pGemT 
(Promega) and checked by sequencing. Primers used were: 
TCMP-1 precursor forward:  
5′-CGGGGTACCATGGCACAAAAATTTACT-3′;  
TCMP-1 precursor reverse:  
5′-TGGGATCCTTATCACACGCCTATGGCCATGGC-3′;  
 
TCMP-1 mature miniprotein forward:  
5′-CGGGGTACCATGCAGCAATATGATCCAGTTTGT-3′;  
TCMP-1 mature miniprotein reverse:  
5′-CGGGATCCTTATTAAACATAGGGCCCACATGTCCCCGCGAA-3′;  
 
GUS forward:  
5′-CGGGGTACCATGTTACGTCCTGTAGAAACC-3′;  
GUS reverse:  
5′-AAGGATCCTCATTGTTTGCCTCCCTGCTGC-3′ 
 
The coding region of TCMP-1 precursor and TCMP-1 mature miniprotein were KpnI-
BamHI (reported in italics in primer sequences) subcloned in the binary vector pBIN19 
downstream to tomato fruit-specific promoter (GenBank accession X13743; Pear et al., 
1989) and followed by the NOS terminator sequence. The recombinant vectors 
(pBIN+TCMP-1 precursor, pBINT1tot; pBIN+TCMP-1 mature miniprotein, pBINT1m; 
pBIN+GUS, pBINGUS) were mobilized into Agrobacterium tumefaciens GV2260.  
STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism version 3.02 software. The 
mean values ± SE or SD are reported in the figures. Statistical analyses were conducted 
using a Student's t-test or two-way ANOVA.  
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R E S U L T S  
AMINO ACIDS SEQUENCE ANALYSIS OF TCMPS  
 
Two cystine-knot miniproteins have been identified in tomato. One, hereafter named TCMP-1 
is a miniprotein of 37 amino acids in its mature form, highly expressed in the flower 
(Martineau et al., 1991), and the other TCMP-2 is a fruit specific miniprotein of 96 amino acids 
containing a predicted N-terminal signal peptide (Pear et al., 1989). 
ClustalW sequence alignment of TCMPs revealed that the mature TCMP-1 miniprotein was 
highly similar to a cystine-knot miniprotein present in potato (i.d. AAC95130; with a 70% of 
amino acid identity) which possesses carboxypeptidase inhibitory activity, while the deduced 
full amino acids sequence of TCMP-2 had high homology with the metallo carboxypeptidase 
inhibitor PFT2 (i.d. BAA21494; 73% amino acid identity), a member of a small family of 
cystine-knot miniprotein present in potato tuber (Figure 5). 
 
Figure 5. Pairwise alignments. Alignments of the deduced amino acid sequences of tomato TCMP -1 
miniprotein and the potato metallo carboxypeptidase inhibitor PCI (upper) and tomato TCMP-2 
miniprotein and metallo carboxypeptidase inhibitor PFT2 (lower). Conserved cysteine residues are 
reported in red. *, residues identical in all sequences; :, for conserved substitutions; ., for semi -
conserved substitutions. The sequences of the recombinant proteins are underlined.  
 
Alignment between TCMP-1 and TCMP-2 showed a relative low degree of homology (29% 
amino acid identity) between the two tomato cystine-knot proteins, however the position of 
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cystine residues, characteristic of the cystine-knot miniproteins were highly conserved 
(Figure 6). 
 
Figure 6. Pairwise alignments. Alignments of the deduced amino acid sequences of tomato TCMP-1 
and TCMP-2 miniproteins. Conserved cysteine residues are reported in red. *, residues identical in all 
sequences; :, for conserved substitutions; ., for semi -conserved substitutions.  
 
FLOWER AND FRUIT DEVELOPMENTAL EXPRESSION PATTERN OF 
TCMP-1 AND TCMP-2  
In Angiosperms, once a flower is pollinated and fertilization has successfully taken place, the 
ovary starts to grow. This is the first visible sign of fruit development (Gillaspy et al., 1993). 
We divided the flower development in 6 stages (Figure 7). 
To investigate the developmental expression patterns of TCMP-1 and TCMP-2 in tomato 
flower, northern blot was carried out using total RNAs isolated from flower buds at the 
various stages. The result showed that TCMP-1 was expressed in flower buds from stage 1 
(flower buds 6-7 days before anthesis) to 4 (anthesis and 1 day post anthesis). The highest 
expression level was detected in flower buds 1-3 day before anthesis (stage 3), and the signals 
then decreased during the flower development. A slight expression of TCMP-1 mRNA is 
present at the stage of young fruit. The signal of TCMP-2 gradually increased after anthesis 
from stage 4 to stage 6 (ovary 0.5-1 cm long), and reached its highest level in tomato fruit. 
We also detected TCMP-1 and TCMP-2 protein accumulation pattern in the same flower 
development stages analyzed by northern blot. The results revealed that during the period 
from stage 3 to stage 6, TCMP-1 protein showed an increasing accumulation, reaching a 
maximum in stage 5 (4-5 days post anthesis). TCMP-2 protein signal was detectable only in 
the tomato fruit, where TCMP-1 protein did not appear.  
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Figure 7. Analysis of TCMPs expression in tomato fruit. Northern blot analysis of the TCMPs mRNA at 
different flower development stages (upper); western blot analysis of the TCMP miniproteins at 
different flower development stages (lower). 1: flower buds 6-7 days before anthesis; 2: flower buds 
4-5 day before anthesis; 3: 1-3 day before anthesis; 4: anthesis and 1 day post anthesis; 5: 4-5 days 
post anthesis; 6: ovary 0.5-1 cm long; fruit: tomato red fruit.  
 
EXPRESSION OF RECOMBINANT TOMATO CYSTINE-KNOT 
MINIPROTEINS TCMP-1 AND TCMP-2 
In order to test the biological activity of the two tomato cystine-knot miniproteins (TCMP-1 
i.d. CAA41973; TCMP-2 i.d.AAA34129), they were expressed as recombinant proteins using a 
bacterial expression system and purified from tomato fruit. The mature 37 amino acid-long 
TCMP-1 miniprotein and the 44 amino acid-long C-terminal portion of the TCMP-2 
miniprotein were expressed in Escherichia coli as His-tag fusion proteins (Figure 8).  
 
Figure 8. Schematic drawing of the construct for the expression of recombinant TCMPs. Restriction 
endonuclease sites used for the recombinant expression construct s are reported. 
 
Results 
42 
 
Several protocols were tested to optimize the expression level, the solubility and the disulfide 
bond formation: different E. coli strains (BL21, BL21 pLysS, OrigamiB), different induction 
times (1,3,5,7,24 hours) and concentration of inducer (0.4-0.7-1 mM IPTG) were considered. 
The recombinant miniproteins were always accumulated as inclusion bodies, irrespective of 
the cloning strategy applied. The inclusion bodies were extracted and solubilised; then the 
target proteins were purified with a nickel affinity column and refolded in vitro. This 
procedure were done on column applying a decreasing gradient of denaturant (guanidine 
hydrochloride 6 M, 30 ml, 0.1 ml min-1). However, the 1H NMR analysis indicated the presence 
of high portion of non well-structured miniproteins (absence of peaks; Figure 9). 
 
Figure 9. 1H NMR spectrum of the TCMP-1. Two milligrams of recombinant TCMP-1 was dissolved in 
300 l of 20 mM phosphate buffer at pH 7.6, containing 10% D2O and the spectrum was recorded at 
25°C in a 500-MHz spectrometer. 
 
In order to improve the solubility of recombinant TCMPs and the yield of the refolding, we 
tested new strategies of expression and refolding. Three approaches were attempted in order 
to obtained soluble/folded TCMPs. The first approach consisted of the expression of the target 
miniproteins as fusion proteins.  
The expression of TCMPs as fusion proteins was obtained using the expression vector pET43 
1a. This vector was designed to express polypeptide sequences fused with the 495 amino acid 
long NusA (Nus•Tag™) protein (Figure 10). The NusA sequence has been reported to enhance 
the solubility of their fusion partners. The Nus•Tag™ vector together with trxB/gor mutant 
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host strains (OrigamiB strains), facilitate disulfide bond formation in the cytoplasm, which 
may help maximize the level of soluble, active, properly folded target protein.  
 
Figure 10. Schematic drawing of the construct for the expression of recombinant TCMPs as fusion 
proteins. Restriction endonuclease sites used for the recombinant expression construct s are 
reported. 
 
Three E. coli strains (BL21, BL21 pLysS, OrigamiB) were transformed with the Nus•Tag™ 
vector carrying the genes for TCMP. The expression was performed at 37°C, with 2 hours 
induction and 0.4 mM IPTG; under these conditions BL21 pLysS did not express the 
recombinant protein, whereas the protein was produced in the BL21 and Origami B 
backgrounds. The cellular localization of the target proteins expressed in BL21 and Origami 
strains was verified (Figure 11). Unfortunately, the highest level of protein was still detectable 
in the inclusion bodies. On the basis of these results the expression of recombinant inhibitors 
as fusion proteins was abandoned. 
 
Figure 11. Expression of recombinant TCMP-1 and TCMP-2 as fusion proteins. Left: SDS-
polyacrylamide gel followed by Coomassie blue staining of the expression of target miniproteins 
assessed by analysis of total cell protein of BL21, BL21pLysS and OrigamiB E. coli strains. M: 
molecular weight marker; I: cells induced with 0.4 mM IPTG; C: control of induction. rT1: 
recombinant TCMP-1; rT2: recombinant TCMP-2. Right: SDS-polyacrylamide gel followed by 
Coomassie blue staining of the sub cellular localization of fusion TCMP-1 and TCMP-2 proteins in 
OrigamiB strain. S: cytoplasmic soluble content; IB: inclusion bodies; rT1: recombinant TCMP-1; rT2: 
recombinant TCMP-2. Arrows indicate the recombinant proteins.  
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An alternative strategy to obtain soluble tomato cystine-knot inhibitors was to use a vector 
that enables the export of the protein in the periplasm, which is a more favourable 
environment for folding and disulfide bond formation. For this purpose the pET12b vector 
carrying a signal sequence for translocation into the periplasmic space was used. At the amino 
terminal of the protein the enterokinase cleavage site was integrated (Figure 12).  
 
Figure 12. Schematic drawing of the construct for the expression of recombinant TCMP -2 in the 
periplasmic space. Restriction endonuclease sites used for the recombinant expression construct are 
reported. 
 
Three E. coli strains (BL21, BL21 pLysS, OrigamiB) were transformed with the pET12b vector 
carrying the genes for TCMP-2. The expression was performed at 37°C, 3 hours induction and 
0.4 mM IPTG. Only the BL21 pLysS strain was able to express the target protein (Figure 13, 
left). However, verification of the sub cellular localization of the target protein and 
purification of the recombinant protein was not easy with host strains containing pLysS, 
because T7 lysozyme damages the cell wall during the manipulation. Western blot analysis of 
the TCMP-2 localisation revealed the recombinant protein in all presumed compartments 
(Figure 13 right) and it was not possible to well define the amount of protein present in the 
periplasm. 
We analyzed the medium as well (Figure 13 right, lane 4), because Molina and collegues found 
that using a vector for the export of potato carboxypeptidase inhibitor into the periplasmic 
space, recombinant PCI was found almost exclusively in the culture medium (Molina et al., 
1992). In our experimental conditions, the concentration of the recombinant protein in the 
culture medium was rather low. Also the approach of expression of recombinant inhibitors in 
the periplasmic space was abandoned, because the purification from the external medium 
would be too laborious. 
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Figure 13. Expression of recombinant TCMP-2 in periplasmic space. Left: SDS-polyacrylamide gel 
followed by Coomassie blue staining of the total cell protein.  M: molecular weight marker; I: cells 
induced with 0.4 mM IPTG; C: control of induction.  Right: western blot of steps during the sub 
cellular localization analysis of expressed proteins in BL21pLysS E. coli strain. 1: whole cell lysate; 2: 
content of the presumed periplasmic space; 3: waste of the purification step of the presumed 
periplasmic space; 4: cell culture medium; 5: denatured inclusion bodies; 6: cytoplasmic soluble 
extract; 7-8: wash steps of the cytoplasmic content isolation. Arrows indicate the recombinant 
protein. 
 
The third approach to increase the yield of the recombinant proteins was the application of a 
new refolding protocol. Bronsoms et al. demonstrated that potato carboxypeptidase inhibitor 
can correctly refold in vitro with kinetics and efficiencies depending on the redox condition 
used, so we decided to apply the same refolding protocol (Bronsoms et al., 2003). After a 5 
hour-long solubilisation of inclusion bodies, the denaturant was eliminated with a desalting 
column and the refolding was done with an overnight 4°C dialysis with a buffer containing 4 
mM cysteine and 2 mM cystine. The day after, the sample was centrifuged and desalted to 
eliminate both cysteine and cystine. Target proteins were purified by means of affinity 
chromatography. Analysis of miniproteins on a SDS-polyacrylamide gel followed by silver 
nitrate staining showed the presence of numerous bands of higher molecular weight. TCMP 
were then isolated with an ultrafiltration step using a membrane with cut off 10 kDa. The 
sample recovered in the filtrate was analysed on a SDS-polyacrylamide gel followed by 
Coomassie blue or silver nitrate staining and it showed an unique band of the correct 
apparent molecular weight (Figure 14). 
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Figure 14. Representative SDS-PAGE of recombinant TCMPs after the refolding protocol with redox 
agents. SDS-polyacrylamide gels followed by silver nitrate staining or Coomassie blue staining 
showing the purity of recombinant TCMPs before and after the ultrafiltration step. M: molecular 
weight marker. Lane 1 is the affinity chromatography eluate pool; lanes 2 and 4 show the presence of 
TCMPs in the sample passed through the membrane 10000 MW stained with Coomassie blue or silver 
nitrate, respectively; lane 3 represents the retained macrosolutes above the membran e 10000 MW. 
Arrows indicate the bands corresponding to TCMPs. 
 
1H NMR analysis of TCMP-2 refolded with this new strategy showed a better-structured 
miniprotein, even if it was not possible to establish if it corresponds to its native 
conformation.  
 
Figure 15. 1H NMR spectrum of the TCMP-2. Two milligrams of refolded TCMP-2 was dissolved in 
300 l of 20 mM phosphate buffer at pH 7.6, containing 10% D2O and the spectrum was recorded at 
25°C in a 500-MHz spectrometer. 
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PURIFICATION OF TCMPS  FROM TOMATO FRUIT 
 
TCMP was also extracted from mature tomato fruits in a two-step procedure including 
homogenization and affinity chromatography against either polyclonal antibody raised 
against TCMP-1 recombinant protein or carboxypeptidase A (Hass and Ryan, 1980). The 
purified miniproteins showed identical electrophoretic mobility irrespective of the 
purification method (data not shown). The analysis of the different fractions obtained during 
immunopurification procedure is shown in Figure 16. 
 
Figure 16. Immunoaffinity purification step of TCMPs from tomato fruit. Proteins were resolved by 
SDS-polyacrylamide gel followed by silver nitrate staining. Lane 1 represent crude tomato fruit 
homogenate; lanes 2-5 are wash fractions; lane 6 represent affinity chromatography eluate pool 
(pure protein preparation). The arrow indicates the band corresponding to the tomato native TCMP s. 
 
The apparent molecular masses of the electrophoretised recombinant miniprotein TCMP-1 
and TCMP-2 and the TCMPs extracted from tomato fruits were consistent with the 
electrophoretic migration of native miniproteins present in tomato fruit crude extract (Figure 
17).  
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Figure 17. Western blot analysis of recombinant TCMP miniproteins. Panel left: TCMP-1. M: 
molecular weight marker; rT1: purified recombinant TCMP-1; T1: flower buds extract. Panel right: 
TCMP-2. M: molecular weight marker; rT2: purified recombinant TCMP-2; T2: TCMP miniproteins 
purified from tomato fruit; TE: tomato fruit crude extract.  
 
INHIBITION OF CARBOXYPEPTIDASE A BY TCMP-2 
Potato carboxypeptidase inhibitor (PCI) competitively inhibits several metallo 
carboxypeptidases with a Ki in the nanomolar range (Hass et al., 1979a). A similar inhibitory 
activity towards carboxypeptidase A (CPAase) was proved for tomato TCMP-1 extracted from 
wound-induced leaves (Díez-Díaz et al., 2004). Potato GM-7 type miniproteins have been 
annotated as metallo carboxypeptidase inhibitors on the basis of their sequence similarity 
with PCI and TCMP-1; nevertheless, their inhibitory activity has not been proved. We 
observed that the recombinant TCMP-2 miniprotein possesses inhibitory activity against the 
bovine carboxypeptidase A (Figure 18).  
 
Figure 18. Inhibitory effect of TCMP-2 on bovine carboxypeptidase A (CPA) activity. PCI: potato 
carboxypeptidase inhibitor,  rT2: 200 nM recombinant TCMP-2; BSA: bovine serum albumin. 
(**P<0.01 versus CPA). Bars indicate SD. 
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INHIBITION OF IN VITRO ANGIOGENESIS BY TCMPS  
Potato PCI is an antagonist analogue of EGF able to inhibit the growth of pancreatic 
adenocarcinoma cells (Blanco-Aparicio et al., 1998). On the basis of the structural homology 
between TCMP miniproteins and potato PCI, current knowledge suggests that these 
miniproteins may display a spectrum of biological effects in human cells related to their 
predictable activity as EGF antagonist. EGF and its receptor (EGFR) are involved in many 
aspects of the development of carcinoma including cell growth and vascularisation. EGFR 
antagonists and blockers can inhibit neo-vascularisation during tumor progression (Michaelis 
et al., 2003). To test the hypothesis that TCMP miniproteins can act as anti-angiogenic 
compounds, we investigated the effects of TCMP miniproteins, both natural and 
recombinants, on in vitro angiogenesis using Matrigel matrix. The EGFR inhibitor AG1478 was 
tested as a positive control. To exclude side effects on capillary tube formation caused by 
bacterial lipopolysaccharides (LPS), recombinant protein preparations were treated with 10 
µg ml-1 polymyxin B, an antibiotic which binds to and neutralizes LPS (Cardoso et al., 2007). 
The selective epidermal growth factor (EGF) receptor blocker AG1478 exhibited a strong 
inhibitory effect on tube formation at 500 nM, indicating that EGF signaling pathway 
activation is a crucial event in capillary network formation. HUVEC and progenitor endothelial 
cells treated with nanomolar concentrations of TCMP miniproteins were not able to form a 
complete vascular network within 24 hours as compared with control (Figure 19).  
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Figure 19. Effects of tomato cystine-knot miniproteins on in vitro angiogenesis. HUVEC grown on 
growth factor-reduced Matrigel were treated with recombinant TCMPs and TCMPs purified from 
mature tomato fruits. Endothelial cells were observed 24 hours after treatment and results were 
recorded digitally.  
 
Quantitative analysis of vascular network length was carried out to characterize the anti-
angiogenic effect of TCMP miniproteins (Figure 20). We found a significant reduction of tube 
length in the presence of TCMP miniproteins at all the concentrations tested (20, 50 and 100 
nM). At the highest concentration (100 nM) the vascular network length was reduced by 64% 
(TCMP-1) and 86% (TCMP-2), respectively as compared with that measured in untreated 
HUVECs. Native TCMP miniprotein, extracted from mature tomato fruit, depressed tube 
formation as well, and the effect was comparable with that of the recombinant miniproteins.  
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Figure 20. Quantitative 
analysis of tube length 
formation. The total tube 
length of a 2.66 mm2 field 
was measured, for each 
treatment 3 fields per well 
were randomly chosen. The 
average tube length was 
calculated analyzing 3 wells 
per treatment (***P<0.001 
versus control). ctrl: control; 
rT1: purified recombinant 
TCMP-1; rT2: purified 
recombinant TCMP-2; fruit: 
TCMP miniproteins purified 
from tomato fruit. Bars 
indicate SD. 
The formation of vascular network was not affected when HUVEC were treated with peptides 
corresponding to the N-terminal (17 amino acids in length) or the C-terminal (20 amino acids 
in length) regions of TCMP-1 (Figure 21), suggesting that the two fragments did not possess 
an intrinsic anti-angiogenic activity and excluding aspecific affects of the miniproteins.  
 
 
 
Figure 21. Quantitative 
analysis of tube length 
formation. The total tube 
length of a 2.66 mm2 field was 
measured, for each treatment 
3 fields per well were 
randomly chosen. The average 
tube length was calculated 
analyzing 3 wells per 
treatment (***P<0.001 versus 
control). ctrl: control; rT1: 
purified recombinant TCMP-1; 
T1 N-terminal and T1 C-
terminal indicate the 
treatment with peptides 
corresponding to the N-
terminal (17 amino acids in 
length) or the C-terminal (20 
amino acids in length) regions 
of TCMP-1, respectively. Bars 
indicate SD. 
 
These results indicate that both recombinant and native TCMP miniproteins exhibit anti-
angiogenic effects at concentrations in the nanomolar range. 
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EFFECTS OF TCMP MINIPROTEINS ON ENDOTHELIAL CELLS 
VIABILITY  
Angiogenesis is a multi-step process that involves a phase of active proliferation of 
endothelial cells. In order to test the effects of TCMP miniproteins on endothelial cell vitality, 
we treated HUVEC with TCMP miniproteins at the concentration of 200 nM and we measured 
cell viability after 24 and 48 hours of culture by MTT assay (WST-8). The recombinant TCMP-
1 miniprotein does not induce any toxic effect on HUVEC (Figure 22). A modest reduction on 
vital cell number (5%) was detected with recombinant TCMP-2 after 24 hours of treatment 
and with TCMP purified from mature tomato fruit after 48 hours of treatment. The two 
synthetic peptides, corresponding to the first 17 N-terminal amino acids and to the last 20 C-
terminal amino acids of TCMP-1, respectively, display a similar modest effect on HUVEC 
vitality. 
 
Figure 22. Effects of tomato cystine-knot miniproteins on HUVEC viability: MTT assay. The average 
percentage of vital cells after 24 and 48 hours of treatment is reported. Ctrl: control; rT1: purified 
recombinant TCMP-1; rT2: purified recombinant TCMP-2; fruit: TCMP miniproteins purified from 
tomato fruit; T1 N-term and T1 C-term indicate the treatment with peptides corresponding to the N -
terminal (17 amino acids in length) or the C-terminal (20 amino acids in length) regions of TCMP-1, 
respectively. Bars indicate SD. 
 
The effects of TCMP miniproteins on HUVEC viability was also assayed using the trypan blue 
exclusion method (data not shown) and the annexin V-propidium iodide assay (Figure 23). 
Annexin V exhibits anti-phospholipase activity and binds to phosphatidylserine, which was 
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exposed at cell surface during the execution of apoptosis. Annexin-FITC labelling allows 
simple direct detection by flow cytometer analysis. Counterstaining by propidium iodide, a 
DNA intercalating agent, allows the discrimination of apoptotic cells.  
 
Figure 23. Dual parameter dot plot of HUVEC stained with annexin V  (AnnexinV-FITC) and 
propidium iodide (PI). Cells were treated for 48 hours with 200 nM TCMP-2. Left: viability plot of 
HUVEC without treatment as control; right: viability plot of HUVEC after treatment  with recombinant 
TCMP-2. 
 
The data obtained with these assays confirmed the absence of significant toxic effects of TCMP 
miniproteins on HUVEC (Figure 24). 
   
Figure 24. Annexin assay. Ctr is the percentage of viable HUVEC without treatment; T2 200 nM 
represents the percentage of viable HUVEC after treatment with 200 nM of recombinant TCMP-2. 
Bars indicate SD. 
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EFFECTS OF TCMP MINIPROTEINS ON ENDOTHELIAL CELLS 
PROLIFERATION 
Cell proliferation was assayed with the incorporation into DNA during active DNA synthesis of 
EdU, a nucleoside analogue of thymidine (Figure 25). Detection is based on a click reaction 
(Breinbauer and Köhn, 2003; Wang et al., 2003), a copper catalyzed covalent reaction 
between an azide and an alkyne. The EdU contains the alkyne, while the dye contains the 
azide. Standard flow cytometry methods are used for determining the percentage of cells in 
the population that are in S-phase. The assay has demonstrated that the treatment with 
TCMP-2 for 48 hours does not affect the proliferation capability of HUVEC cells. 
 
 
Figure 25. EdU Proliferation assay. Ctr 
represents the percentage of 
proliferating HUVEC without treatment; 
T2 200 nM is the percentage of HUVEC 
after treatment with 200 nM of 
recombinant TCMP-2. Bars indicate SD. 
As an independent control, the growth of HUVEC cells was followed up to 96 hours in the 
presence of TCMP-2 at a concentration of 200 nM. The treatment did not affect cell 
proliferation (Figure 26). 
 
 
Figure 26. Cell count. 
Number of HUVEC per 
well 24, 48, 72, 96 
hours after treatment 
with 200 nM TCMP-2. 
Bars indicate SE. 
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These data indicate that TCMP miniproteins do not significantly affect HUVEC proliferation, 
suggesting that the anti-angiogenic effect does not depend on the inhibition of cell 
proliferation or viability. 
 
EFFECT OF TCMPS  ON EGFR SIGNALING PATHWAY 
EGFR signal transduction cascade is implicated in angiogenesis; oncogenic EGFR contributes 
to angiogenic phenotype of cancer cells (Al-Nedawi et al., 2009). The cystine-knot potato 
carboxypeptidase inhibitor at concentrations of about 10 µM was reported to interfere with 
EGFR activation through inhibition of receptor transphosphorylation induced by EGF (Sitjà-
Arnau et al., 2005). To investigate the mechanism underlying the anti-angiogenic effect 
displayed by TCMPs, we monitored the phosphorylation state of EGFR in the presence of the 
same TCMPs concentrations used in the angiogenesis assay. One fundamental signaling 
pathway downstream EGFR activation is mitogen activated protein kinase (MAPK) cascade. 
Therefore we also examined the phosphorylation state of ERK1/2, one of the main effector 
proteins downstream to EGFR, to determine whether TCMP affect the MAPK pathway.  
EGFR-overexpressing A431 cells were incubated for 30 minutes with nanomolar 
concentrations of PCI, recombinant TCMP-2 and AG1478 alone or 30 minutes with nanomolar 
concentrations of PCI, recombinant TCMP-2 and AG1478 and 5 or 15 minutes with EGF to test 
their activity on EGFR phosphorylation or on ERK1/2 and Akt phosphorylation, respectively. 
The EGFR specific inhibitor AG1478 at a concentration of 500 nM completely blocked the 
receptor transphosphorylation induced by EGF. PCI at the concentration of 500 nM was not 
able to block the autophosphorylation of EGF-stimulated EGFR. Similarly, recombinant TCMP-
2 (100-500 nM) did not depress EGFR activation. Moreover, cells treated with TCMP-2 
concentration greater than 100 nM or with PCI showed autophosphorylation of the EGF 
receptor (Figure 27).  
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Figure 27. Western blot analysis of phospho-EGFR (pEGFR) performed on A431 cells treated with 
different concentrations of TCMP-2 (rT2). The ratio of the densities (phosphorylated form/total protein) 
is shown in the lower table. The experiments were performed at least twice and a representative 
example is shown. 
 
Both PCI and TCMP-2 had only minor effects on ERK1/2 phosphorylation when they were 
supplied in combination with EGF, but they showed an inhibitory activity when used alone. 
This inhibitory effect was more evident on ERK1 (Figure 28). 
 
Figure 28. Western blot analysis of phospho-ERK1/2 (pERK1/2) performed on A431 cells treated 
with different concentrations of TCMP-2 (rT2). The ratios of the densities (phosphorylated form/total 
protein) are shown in the lower table. The experiments were performed at least twice and a 
representative example is shown.  
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Every tested concentration of TCMP-2 and PCI had very little or no effect on Akt 
phosphorylation when A431 cells were inoculated with EGF (Figure 29).  
 
Figure 29. Western blot analysis of phospho-Akt (pAkt) performed on A431 cells treated with 
different concentrations of TCMP-2 (rT2). The experiments were performed at least twice and a 
representative example is shown.  
 
These data suggest that TCMP-2 and PCI in the nanomolar range interfere with MAPK 
signaling pathway affecting ERK1/2 activation and not Akt phosphorylation, and this effect is 
not the consequence of an inhibitory action on EGFR phosphorylation. 
 
TCMP MINIPROTEINS INHIBIT ERK1/2 PHOSPHORYLATION  
To test whether TCMP miniproteins can interfere with MAPK pathway of endothelial cells, 
EGF-stimulated HUVEC cells were treated with nanomolar concentrations of recombinant 
TCMPs and the phosphorylation level of ERK1/2 was examined. The results show that 
phospho-ERK1/2 decreased after treatment with recombinant TCMP miniproteins at 100 nM 
(Figure 30, panel left). The same effect was obtained after treating HUVEC with PCI at 100 nM. 
The effect produced by TCMPs on phospho-ERK1/2 level was weaker than that observed in 
HUVEC treated with the EGFR specific inhibitor AG1478 at 500 nM. The inhibitory effect of 
TCMPs was particularly evident against ERK1.  
TCMP extracted from mature fruits showed an inhibitory effect on ERK1/2 phosphorylation 
similar to that observed with recombinant proteins (Figure 30, panel right).  
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Figure 30. Western blot analysis of p-ERK1/2 performed on HUVEC treated with TCMPs. Panel left: 
HUVEC treated with recombinant TCMP-1 (rT1) and TCMP-2 (rT2); Panel right: HUVEC treated with 
TCMPs purified from tomato fruit (fruit TCMPs). The ratio of the densities (phosphorylated 
form/protein) are shown in the lower panel of each western blot.  The experiments were performed at 
least twice and a representative example is shown. 
 
These data suggest that the anti-angiogenic effect exerted by TCMPs is associated to the 
alteration of MAPK signaling pathway.  
Only the non-phosphorylated form of Akt was detected in HUVEC despite the use of different 
lysis buffers and different amount of cell lysate loaded on SDS-PAGE. pEGFR, EGFR gave no 
signals. Although evidence suggests a direct effect of EGF on endothelial cells, the expression 
and function of EGFR in this cell type is still debated. Several studies have failed to 
demonstrate expression of EGFR in HUVEC (Hirata et al., 2002; Amin et al., 2006); however, 
Sini and colleagues have demonstrated that stimulation of HUVEC with EGF led to an increase 
of EGFR phosphorylation and ERK1/2 activation (Sini et al., 2005). Some authors concluded 
that heterogeneous results on the expression of EGFR in endothelial cells might be relate to 
differences between individuals as well as to cell culture variability. However, activation of 
EGFR signaling in endothelial cells could occur in specific physiological situation. 
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TCMP-1 EXPRESSION IN TOMATO FRUIT  
In order to increase the TCMPs content of tomato fruit, we planned to stably transform Micro-
Tom plants with a construct containing the TCMP-1 gene under the control of a tomato fruit 
specific promoter.  
Micro-Tom is a miniature dwarf tomato cultivar that has several unique features, such as a 
small size that enables it to grow at a high density, seed setting under fluorescent light and a 
short life cycle that allows for mature fruit to be harvested within 70–90 days after sowing.  
TCMP-1 encodes for a 643 base-long mRNA which produces a putative protein of 77 amino 
acid residues (Figure 31). On the basis of the protein sequence (CAA41973.1), the molecular 
mass is estimated to be approximately 8.3 kDa with an isoelectric point of about 6.5. TCMP-1 
protein is predicted to have a N-terminal 37 residue-long signal peptide, which is excised 
(Figure 31) and most likely targets the mature protein towards the secretory pathway, 
consistent with what has been observed for other proteins containing the same hydrophobic 
signal sequence associated with transport of the nascent polypeptide across the rough 
endoplasmic reticulum (von Heijne, 1983). TCMP-1 protein is predicted also to have a C-
terminal 8 residue-long extension for vacuolar sorting (Figure 31). 
 
Figure 31. TCMP-1 sequences. Upper panel: nucleotide sequence of the mRNA encoded by TCMP-1 
gene. Middle panel: amino acid sequence of TCMP-1 protein. Lower panel: amino acid sequence of 
TCMP-1 with in bold N-terminal signal peptide and C-terminal extension.  
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Two distinct constructs were done to express in tomato fruit either the precursor (pBINT1tot) 
or the mature form of TCMP-1 (pBINT1m). The constructs were placed under the control of 
TCMP-2 promoter which has been demonstrated to be fruit specific (Pear et al., 1989). As 
control of the promoter activity, a third construct containing the coding region of the GUS 
gene under the control of the TCMP-2 promoter was created (pBINGUS).  
pBIN19 carries the lacZ’ gene, the kanamycin-
resistance gene (kanR), an E. coli origin of replication, 
and the two boundary sequences from the T-DNA 
region of the Ti plasmid. These two boundary 
sequences recombine with plant chromosomal DNA, 
inserting the segment of DNA between them into the 
plant DNA. The orientation of the boundary 
sequence in pBIN19 means that the lacZ’ and kanR 
genes, as well as any new DNA ligated into the 
restriction sites within lacZ’, are transferred to the 
plant DNA (Figure 32).  
 
Figure 32. pBIN19 map.  
pBIN is an example of a shuttle vector, recombinant molecules being constructed in E. coli, 
using the lacZ’ selection system, before transfer to Agrobacterium tumefaciens and hence to 
the plant. Subsequently, recombinant plant cells are selected by plating onto kanamycin agar, 
and then regenerated into whole plants. 
TCMP-1 and GUS coding region were amplified using PCR adding the KpnI restriction site at 
the 5’ end and the BamHI restriction site at the 3’ end. The tomato fruit-specific promoter 
sequence was also amplified by PCR adding the EcoRI and KpnI restriction sites at the 5’ and 
3’ end, respectively. The resulting amplicons were cloned into linearized plasmid pGemT and 
checked by sequencing. The recombinant genes and promoter were subsequently digested 
with restriction enzymes EcoRI, KpnI and BamHI and introduced into the binary vector 
pBIN19 carrying the NOS terminator as indicated in Figure 33a. The three recombinant 
plasmids where checked by DNA sequencing and introduced in Agrobacterium tumefaciens 
GC2260. The introduction of the recombinant binary vectors in A. tumefaciens was verified by 
PCR (Figure 33b). 
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Figure 33. A: Scheme of the chimeric genes created for tomato transformation. B: Agarose gel 
electrophoresis of PCR products obtained from plasmid pBINT1m and pBINT1tot extracted from 
Agrobacterium tumefaciens  GC2260. M: molecular weight marker; T1m: TCMP-1 mature sequence; 
T1tot: TCMP-1 precursor sequence; C: PCR control.   
 
Transformation of cotyledon explants of tomato with Agrobacterium tumefaciens GC2260 
harbouring the vector pBINT1tot or pBINT1m or pBINGUS and the molecular identification of 
transformed plant will be the objective of future experiments. 
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D I S C U S S I O N  
A successful nutrition intervention could have a profound impact on the improvement in the 
quality of life. Evidence for ‘food’ prevention is derived from animal testing and in vitro assays, 
whereas human clinical trials are still scarce. Some key issues such as bioavailability, 
metabolism, dose/response and toxicity of these food bioactive compounds have to be well 
established and a great deal of research is needed to determine the mechanisms by which 
natural compounds present in human diet may delay or prevent the onset of diseases.  
In the present research, we investigated the biological action of two tomato cystine-knot 
miniproteins which are present in the edible parts of tomato and consequently are 
components of our diet. Our attention was addressed to angiogenesis, since the identification 
of new angiogenesis inhibitors endowed with low toxicity may represent a relevant goal in 
cancer prevention and therapy.  
Our characterization of the cystine-rich miniproteins derived from tomato (TCMP-1 and 
TCMP-2) first considered the expression pattern of the two proteins. Until now, few studies 
have been performed to investigate cystine-knot miniprotein expression in tomato during 
fruit development. Previous investigations reported that TCMP-1 is present at high level in the 
tomato ovary (Martineau et al., 1991) and the mRNA of a putative sulfur-rich protein 
accumulates in tomato fruit (Pear et al., 1989). Our results show that TCMP-1 gene is not 
constantly expressed in all flower development stages, but has an increasing trend during 
flower bud development, with the highest mRNA level in flower buds 1-3 days before 
anthesis. After anthesis, the expression of TCMP-1 gene is down-regulated. The expression 
pattern of TCMP-1 protein is shifted with respect to gene expression, since the highest level of 
protein was detected in flower buds 4-5 days after anthesis. TCMP-2 gene is expressed at the 
onset of fruit development and reaches the maximum level in tomato mature fruit. TCMP-2 
protein is detectable only in the fruit. Our data indicate that TCMP-1 protein plays its role 
during tomato flower development and in the first phases of fruit growth, whereas TCMP-2 is 
a fruit specific protein that accumulates in the fruit at the stage of maturation.  
The biological characterization of tomato cystine-knot miniproteins was carried out using 
recombinant TCMP-1 and TCMP-2 expressed in a bacterial system as well as proteins 
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extracted from tomato fruits. The recombinant expression of TCMP-1 and TCMP-2 
represented an important challenge due to the small size of the proteins and the presence of 
disulfide bonds, which may affect protein solubility inside the bacterial cell and lead to 
misfolding and subsequent aggregation. We tested different approaches for the successful 
recombinant expression and the better strategy results for both miniproteins in the use of the 
specialized expression vector pET12b based on the T7 promoter-driven system originally 
developed by Studier and colleagues (Studier et al., 1990). Two different host strains were 
used for optimizing the expression of TCMP-1 and TCMP-2. High yield of TCMP-1 was 
achieved in OrigamiB (DR3), a bacterial strain which carries glutathione reductase and 
thioredoxin reductase mutations that enhance the formation of disulfide bonds in the E. coli 
cytoplasm. For TCMP-2 the highest expression was obtained in BL21(DR3) pLysS, a strain that 
contains a compatible plasmid that provides a small amount of T7 lysozyme, a natural 
inhibitor of T7 RNA polymerase for a high-stringency expression. Both TCMP-1 and TCMP-2 
are accumulated in inclusion bodies. After denaturation of the inclusion bodies, the 
renaturation in a refolding buffer containing redox agents was proved to be good choice, as it 
was previously described for the refolding of recombinant potato carboxypeptidase inhibitor 
(Bronsoms et al., 2003). Isolation of TCMPs from mature tomato fruits is favoured by the 
natural stability and resistance to proteolytic attack of the two miniproteins. However, the 
purification process is quite long and laborious and requires the processing of a large amount 
of tomato fruits. The yield of production is about 6.6 mg/kg tomato fruit. 
To explore the effects of TCMPs on endothelial cells, we first analyzed the effects of these 
cystine-knot miniproteins on in vitro angiogenesis using both human umbilical vein 
endothelial cells (HUVEC) and human progenitor endothelial cells. We have seen that TCMPs 
extracted from tomato and recombinant TCMP-1 and TCMP-2 exert the same biological action, 
that is they are able to strongly inhibit tube formation. Both recombinant and fruit-extracted 
TCMPs work at nanomolar concentration, suggesting biological relevance. Neither the N-
terminal nor the C-terminal part of TCMP-1 possess biological activity per se, so we can 
assume that for the anti-angiogenic activity, the integrity of the mature part of the 
miniproteins is required. The presence of intra-molecular disulfide bonds might be important 
for the biological function of TCMPs. 
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The emergence and maturation of new vessels are extremely complex and coordinated 
processes requiring successive activation of cellular events coordinated by numerous signals. 
Angiogenesis begins from local destruction of the wall of preexisting blood vessel, activation 
of endothelial cell proliferation, and migration. Every single event is a possible target for an 
anti-angiogenic effect and to clarify the effect of TCMPs we first investigated the effects of 
TCMPs on cell proliferation and viability. The present research demonstrates that inhibition 
of angiogenesis by TCMPs is not due to an interference in cell physiological state. TCMPs 
inhibit angiogenesis in in vitro 2D tube formation assay without altering HUVEC proliferative 
capability and without increasing cell apoptosis. Moreover, TCMPs are not toxic for 
endothelial cells, because the viability of HUVEC cells, even in the presence of TCMPs 
concentrations higher than those necessary for inhibiting angiogenesis, is not altered. 
It is well known that the angiogenic process requires, like other biological processes, 
successive activation of rather a large series of receptors and numerous ligands and a finely 
adjusted balance between multiple stimulating and inhibitory signals. One of the most 
important signal pathways is mediated by VEGF receptor and its ligand VEGF, but many other 
signaling pathways beyond this are implicated in the formation of new vessels and angiogenic 
response. They include fibroblast growth factor-2 (FGF-2), epidermal growth factor (EGF) and 
several anti-angiogenic factors. The role of EGFR signaling pathway in angiogenesis has been 
the object of several studies over the past few years. These studies have shown both a direct 
and an indirect role of EGF-mediated signaling in angiogenesis (Mehta and Besner, 2007; 
Fujiyama et al., 2001). Blanco-Aparicio et al. reported that potato carboxypeptidase inhibitor 
(PCI), a cystine-knot miniprotein, is an antagonist of EGF. It competed with EGF for binding to 
EGFR and inhibited EGFR activation and cell proliferation induced by this growth factor 
(Blanco-Aparicio et al., 1998). In a subsequent study it was shown that PCI at micromolar 
concentration interferes with EGFR activation through the inhibition of receptor dimerization, 
receptor internalization, and receptor transphosphorylation induced by EGF (Sitjà-Arnau et 
al., 2005). TCMP-1 is highly homologous the cystine-knot miniproteins PCI of potato (PCI) and 
TCMP-2 shows a high similarity with members of the cystine-knot miniprotein family 
identified in potato tubers. Based on these similarities, the hypothesis that the anti-angiogenic 
action displayed by TCMPs could be linked to inhibition of EGFR phosphorylation is 
reasonable. However, this hypothesis was not supported by our experimental data. 
Nanomolar concentrations of TCMPs did not depress EGFR phosphorylation induced by EGF 
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in A431 cell lines and did not depress phosphorylation of the downstream protein Akt. 
However, in both HUVEC and A431 lines threonine phosphorylation of ERK1/2 was inhibited. 
Ras/MAPK and PI3K/Akt pathways are the transduction pathways primarily involved 
downstream EGFR activation, and phosphorylation of ERK1/2 occurs after the engagement of 
EGFR in human endothelial cells (Mehta et al., 2007). However, phosphorylation of ERK1/2 
occurs also after receptor activation by other ligands, such as fibroblast growth factor (FGF) 
or VEGF (Slevin et al., 2000). Our data cannot exclude a direct or indirect action of TCMPs on 
MAP kinase signaling triggered by either FGF or VEGF.  
The alternative hypothesis of the TCMPs’ involvement in angiogenesis inhibition is supported 
by their biochemical activity as metallo carboxypeptidase inhibitors. TCMP-1 and PCI are 
known to be inhibitors of metallo carboxypeptidases and we have shown that also TCMP-2 
possesses such biochemical activity. The formation of new vessels requires degradation of 
cytoskeleton extracellular matrix and the removal of obstructing matrix proteins to allow the 
formation of the vessel lumen. The proteolytic activity of matrix metalloproteinases (MMPs) 
are a key component of these processes, both in physiological and pathological conditions 
(Visse and Nagase, 2003; Galis and Khatri, 2002). The biological activity of MMPs must be 
tightly regulated if we consider that the MMP family is capable of degrading all the individual 
component of blood vessel extracellular matrix. Recent efforts have focused on finding ways 
to control the action of vascular MMPs through the use of nonspecific synthetic inhibitors 
(Galis et al., 1998; Zempo et al., 1994) or of natural inhibitors (Allaire et al., 1998; Baker et al., 
1998; Forough et al., 1998). It will be interesting to test whether the metalloendopeptidase 
inhibitor activity of TCMP proteins contributes to their anti-angiogenic properties. 
To summarise, we have demonstrated that tomato cystine-knot carboxypeptidase inhibitors 
both native and recombinant, possess anti-angiogenic activity in vitro. The tomato 
miniproteins act as an anti-angiogenic factor in the nanomolar concentration range, which is 
of particular biological relevance. Since tomato cystine-knot carboxypeptidase inhibitors are 
normal components of edible fruits, these compounds should be endowed with low toxicity 
when tested in animal models of disease and in humans. Tumorigenic angiogenesis could 
represent a target for therapeutic intervention with tomato miniproteins, and their anti-
angiogenic activity could be tested as well for the prevention of other diseases. On these 
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bases, miniproteins from tomato may be of potential pharmacological interest and deserve 
further investigation. 
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